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SUMMARY 
Hepatocellular carcinoma ranks fifth in frequency among all malignancies 
worldwide. In Singapore it is also one of the commonest primary cancers. HBV 
and HCV are major risk factors for the carcinogenesis. The patients with 
intermediate and advanced HCC often has poor prognosis. More effort is still 
needed in discovering biomarker for early diagnosis and therapy. 
The two cell lines, HepG2 and HCC-M, both possess the same histological type 
which is of the epithelial type. However, they are from different origins, the 
former was established from extended lobectomy of a 15-year-old Caucasian 
male from Argentina, while the latter was derived from a hepatocellular 
carcinoma of an HBsAg-positive Japanese adult male. They have some 
different biological characteristics from each other. 
Butyrate is a potent differentiation inducer which inhibits proliferation of a 
wide variety of cancer cells in vitro and in vivo. In addition, it also affects gene 
expression and cell cycle protein regulation, and induces apoptosis. There were 
some earlier biological studies on the effect of butyrate on the two cell lines, but 
there were no comparative studies between them at the proteomic level. 
The present study is focused on the response of the two cell lines to the 
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treatment of butyrate by monitoring the change in protein expression by a 
proteomic approach.  
We used MTT assay and found that both cell lines’ viabilities were inhibited by 
butyrate in a dose- and time-dependent manner. 5mM butyrate could 
completely inhibit HCC-M cell growth, while HepG2 cells’ growth was only 
partially inhibited.  
Through apoptotic assay using Annexin-V-FLUOS kit and flow cytometry, we also 
observed that after 5mM butyrate treatment for 48 hours, HCC-M cells showed 
the highest apoptotic change. However, for HepG2, there was an increasing 
level of apoptotic change, but it was still lower than HCC-M after 72 hours.  
Protein expression differences between the control and treated cells of both 
hepatoma cell lines were analyzed by 2-dimensional difference gel 
electrophoresis (2-D DIGE). The spots of differentially expressed protein were 
subsequently excised for mass spectrometric analyses and identification. 
Up-regulation of RGS19 interaction protein1 and down-regulation of 
calmodulin were found only in the butyrate-treated HCC-M cells. RGS19 
interaction protein1 can selectively interact with the Gα subunit of G protein 
and inhibit the voltage-independent calcium channel, which may induce a 
decrease in inner calcium concentration of the cells. Cytosolic calcium 
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homeostasis and a stable level of calmodulin expression are necessary for cell 
proliferation. 
Thus our results suggest that HCC-M cells’ sensitivity to butyrate treatment, as 
compared to HepG2 cells, may be related to the calcium signaling pathway. 
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1.1 Liver cancer 
1.1.1 What is liver cancer? 
The liver is one of the major organs of the body, and is crucial to life (hence the 
name “live-r”). It is involved in many processes of the body such as manufacturing 
various essential proteins, processing and storing nutrients, destroying toxins and 
poisons among others. The liver is made up of many different cell types but the two 
main ones are liver cells (hepatocytes) and cells lining the bile ducts 
(cholangiocytes).  
Like any other part of the body, the cells in the liver can undergo changes to form 
cancer. Liver cells that become cancerous form liver cancer (hepatocellular 
carcinoma, HCC). Bile duct cells change into the cancerous cholangiocarcinoma. 
Cancerous cells that originated from other parts of the body and spread to the liver, 
for example, colon cancer, do not constitute liver cancer in the strict sense. These 





   - 3 - 
1.1.2 How common is liver cancer? 
Liver cancer is the fifth commonest cancer worldwide (Parkin et al., 2001). In 
Singapore it is the fourth commonest cancer among men. It affects about 14 
individuals in every 100,000 people a year. Liver cancer is mainly an Asian disease, 
and is common in South-East Asia, China, Japan and Korea. It is also common in 
parts of Africa and the Mediterranean countries (especially Italy). 
Table 1-1 Incidence and mortality of five common cancers worldwide, 2000 
Note: Numbers of cases and deaths (1000s) include HCC and cholangiocacinoma 
(<10%). Modified from Parkin D.M. et al., 2001. 
 
1.1.3 Age of onset 
Liver cancer presents itself mainly in the older age group, such as from the 40s to 
50s. It can also affect a younger individual who has contracted hepatitis B or C 
from birth or in those with certain congenital conditions (Lee et al., 1993; Parkin, 
2002). 
Site Incidence (%) Mortality (%) 
Lung 1238.9 (12.3) 1130.1 (17.7) 
Breast 1050.3 (10.0) 373.0 (6.0) 
Colon/rectum 944.7 (9.4) 492.4 (7.9) 
Stomach 876.3 (8.7) 646.6 (10.4) 
Liver 564.3 (5.6) 548.6 (8.8) 
All sites 10055.6 (100) 6208.7 (100) 
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1.1.4 Risks and causes 
The three main causative factors for liver cancer are hepatitis B carrier status, 
hepatitis C infection and alcoholic liver disease. Other rare causes include poisons 
(aflatoxin) from fungus growing in badly preserved food (especially grains), 
congenital conditions (alpha-1 anti-trypsin deficiency), and any cause of liver 
hardening or cirrhosis (e.g. haemachromatosis) (Bosch, 2002). 
The risk of an individual with hepatitis B or C infection of getting liver cancer is 
100 times higher as compared to a normal person. The pattern of liver cancer 
worldwide follows closely with the pattern of hepatitis B and C infections. In 
countries where immunization for hepatitis B has been started, the number of liver 
cancer seen a year have also fallen in line with a fall in the number of hepatitis B 
cases. Hepatitis B can be transmitted from an infected mother to her baby during 
pregnancy. In the adult setting, hepatitis B and C can be transmitted by contact 
with infected body fluids, e.g. saliva, blood, sperm and other secretions (Alter, 
2003). Blood transfusion is no longer a risk factor because of adequate screening 
methods in Singapore. 
Alcohol is the main cause for liver cancer in the Western population. The liver is 
damaged by repeated and excessive alcohol abuse leading to liver hardening 
(cirrhosis) and carcinogenesis (Di Bisceglie et al., 1998). 
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1.2. Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) represents the vast majority of liver cancer, 
accounting for more than 90% of all primary liver cancers, and ranks fifth in 
frequency among all malignancies worldwide (Schafer et al., 1999; Okuda, 2000). 
Years ago, HCC was considered a major health problem in Asia and Africa, with 
only a minor prevalence in Europe or America. However, current data indicated 
that its incidence is steadily increasing in the West (Parkin et al., 2001). 
1.2.1 Epidemiology and risk factors 
The incidence of HCC has a wide geographical variation due to the large 
heterogeneity of the penetration of the risk factors within the population (Llovet, et 
al., 2003). Any agent leading to chronic liver injury, and eventually cirrhosis, 
constitutes an oncogenic agent. The most relevant are hepatitis B (HBV) and 
hepatitis C (HCV) viruses and alcohol (Table 1-2). Figure 1-1a (CDC, 2002) and 1-
1b (WHO. 2000) showed the world distribution of HBV and HCV infection, 
respectively. Other causes of hepatocyte damage (iron or copper deposition, non-
alcoholic steatohepatitis, or primary biliary cirrhosis), are also risk factors, but their 







Table 1-2 Incidence of HCC according to geographical area and distribution of risk factors.  
Age-adjusted incidence rates Risk factors Geographic area 
Male Female HCV HBV Alcohol Others 
Europe   60%-70% 10%-15% 20% 10% 
Western Europe 5.8 1.6     
Southern 9.8 3.4     
Northern 2.6 1.3     
North America   50%-60% 20% 20% 10% 
Southern 4.1 1.6     
Northern 4.8 3.6     
Asia and Africa   20% 70% 10% Aflatoxin 
Singapore 4.0 1.0  80%   
Eastern Asia 35.4 12.6     
South-Eastern Asia 18.3 5.7     
Middle Africa 24.2 12.9     
World 14.9 5.5  
















           
                          
Figure 1-1a. Global distribution of chronic HBV infection, 2000                          Figure 1-1b. Global distribution of chronic HCV infection, 2001 
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1.3. Hepatocellular carcinoma cell lines 
1.3.1 HCC-M cell line 
HCC-M was established from a hepatocellular carcinoma of an HBsAg-positive 
34-year-old Japanese male (Watanabe et al., 1983). The cell line grows as an 
adhering monolayer with a doubling time of 24 h in RPMI-1640 medium 
supplemented with 10% FCS and grows with a 30% clonal efficiency in soft agar. 
The cells have been shown by light and electron microscopy to be of the epithelial 
type. When they were transplanted subcutaneously into the back of athymic nude 
mice (BALB/c, nu/nu), tumors developed at the sites of inoculation. They were 
shown to be hepatocellular carcinoma, similar in morphology to the original tumor 
from which they were derived. HCC-M had a chromosome mode of 63 with five 
identifiable marker chromosomes. HCC-M produced albumin at the 10th passage 
but this property was lost by the 30th passage. This cell line does not secrete alpha-
fetoprotein. Hepatitis B viral particles or HBsAg have not been demonstrated in the 
cells from the primary culture or in several subsequent subcultures tested. However, 
HCC-M contains the genomes of hepatitis B virus (HBV) in an integrated form. 
(Morizane et al., 1987) N-, H-, K-ras and myc transcripts were detected in the cell 
line. (Saito et al., 1991) HCC-M expresses mRNA for both IL-6 and IL-6 receptor, 
and IL-6 acts as an autocrine growth factor for HCC-M cells (Kumagai et al., 
2002).  
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1.3.2 HepG2 cell line 
HepG2 was established from liver tumor biopsies obtained during extended 
lobectomy of a 15-year-old Caucasian male from Argentina in 1975. Histology of 
the liver biopsies revealed well differentiated hepatocellular carcinoma with a 
trabecular pattern (Aden et al., 1979). The cell line can be cultured as an adhering 
monolayer in minimum essential medium (Eagle) with 2 mM L-glutamine and 
Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1mM non-essential 
amino acids, and 1.0mM sodium pyruvate, plus 10% fetal bovine serum. HepG2 
can secrete alpha-fetoprotein, albumin and hepatitis B surface antigen (Knowles et 
al., 1983) and express 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic 
triglyceride lipase activities (Busch et al., 1990), and demonstrate decreased 
expression of apoA-I mRNA and increased expression of catalase mRNA in 
response to gramoxone (oxidative stress) (Cuthbert et al., 1997). There is no 
evidence of a Hepatitis B virus genome in this cell line (Aden et al. 1979, Knowles 
et al., 1980). Insulin-like growth factor II receptor mRNA was expressed 
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1.4 Butyrate 
Butyrate is a short-chain fatty acid produced by bacterial fermentation in the 
mammalian colon (Cummings et al., 1987). It inhibits cell proliferation and 
stimulates cell differentiation (Hague et al., 1993). It also affects many 
physiological processes in cultured mammalian cells, among these are the 
transcriptional activation of previously inactive genes and also the inactivation of a 
few active genes (McKnight et al., 1980), reversible differentiation of cells (Prasad 
et al., 1975) and blocking of cells in the G1 phase of the cell cycle (Xue et al., 
1981). It has been reported that while sodium butyrate can induce hypomethylation 
of genomic DNA in some cell systems (Cristman et al., 1980), but it can also cause 
hypermethylation in others (Parker et al., 1986). Additionally, sodium butyrate has 
been shown to suppress deacetylation of histones (Vidali et al., 1978). 
1.5 The effect of butyrate on HCC-M and HepG2 
As a cell differentiation inducer, butyrate is a potential therapeutic agent for liver 
cancer. There are some published studies about the effect of butyrate on the cell 
model HCC-M and HepG2. 
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1.5.1 The effect of butyrate on HCC-M 
Butyrate, as a well-known cell differentiation inducer, seemed to induce normal or 
mature properties of hepatocytes in human hepatoma cell lines. C-myc expression, 
which was enhanced in the naive state, was reduced, and Fos expression was 
inhibited (Saito et al., 1991). The expression of liver-specific antigen, H2, could 
react more strongly with the non-neoplastic region than the neoplastic region. H2 
increased in HCC-M cell after butyrate treatment, and the effect may be related to 
c-myc-signal pathway (Saito et al., 1994; Ebinuma et al., 1999). P53 expression is 
decreased and the expression of p21WAF-1 and bcl-2 were increased, which 
further suggests butyrate induces HCC-M differentiation, not apoptosis (Saito et al., 
1998). Butyrate also up-regulates the expression of E-cadherin and β-catenin which 
are potent inhibitors of hepatocellular carcinoma cell invasion and metastasis 
(Masuda et al., 2000). 
1.5.2 The effect of butyrate on HepG2 
Incubation with 10mM butyrate for 30hours can inhibit the DNA synthesis of 
HepG2 cell reversibly (Donadel et al., 1991). Incubation with 1mM butyrate for 2 
days increases the production and secretion of cholesteryl-ester-transfer protein 
(CETP) which is crucial in human high-density lipoprotein metabolism (Sperker et 
al., 1993). Incubation for 72hours inhibited cellular proliferation and both 
glutamine transport and glutaminase activity which are more active in hepatoma 
Chapter I            
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cell than in normal human hepatocyte (Bode et al., 1994). Treatment with 35mM 
butyrate for 24hours induces growth arrest, differentiation and eventual apoptosis 
and the Bcl-2 protein level is decreased despite no change in mRNA level. The 
Cdk inhibitor p21waf1 and p27kip1 levels are increased by p53 independent pathway 
(Wang et al. 1998, 1999). Treatment with 2.5mM butyrate for 48hour decreases the 
human γ-glutamyltransferase (GGT) activity, and GGT could play an important 
role in maintaining cell proliferation in transcription level (Daubeuf  et al., 2001). 
Butyrate increases proline-rich acidic protein (PRAP) gene expression in cancer 
cell lines. The gene is suppressed through epigenetic mechanisms involving histone 
deacetylation and methylation (Zhang et al., 2003). 
1.6 Proteomics 
The word “proteome” was coined by Marc Wilkins and Keith Williams of 
Mcquarie University in Sydney, Australia, in 1995 (Wasinger et al., 1995).  The 
definition of a "proteome" is simply the PROTEin complement of a genOME 
expressed by a cell or tissue.   Like the word “genome”, which refers to the total 
number of genes in an organism, proteome refers to the total protein complements 
of the genome.  “Proteomics”, meanwhile, refers to the large-scale study of 
proteins, usually by biochemical methods. 
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1.6.1 The significance of proteomics studies 
There have been a number of revolutions in molecular biology in the past few 
decades. The completion of the immense effort to sequence the human genome was 
the Most recent one (Lander et al., 2001, Venter et al., 2001). However, in the last 
few years, it has become widely recognized that the genome only represents the 
first layer of complexity. Biological function is not carried out by the static genome 
but mainly by the dynamic population of proteins determined by interplay of gene 
and protein regulation with extracellular influences. The list of matured proteins, 
including splice variants and post-translational modifications, cannot be predicted 
from the genome sequence. There are numerous instances of differential splicing 
and many post-translational protein modifications (e.g., phosphorylation, 
glycosylation, ubiquitination, and methylation) that can govern the behavior of 
proteins more than differing rates of synthesis. Although mRNA profiling through 
microarrays offers immense potential for increasing the understanding of molecular 
changes that occur during biological processes including disease progression, it 
does not capture mechanisms of regulation involving changes in cellular 
localization, sequestration by interaction partners, proteolysis, and recycling. For 
these reasons, there is increasing interest in the field of proteomics, or the large-
scale study of proteins as a complement to genomics and functional genomics. 
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1.6.2 Proteomics strategies  
In the early days, proteomics was mainly based on the combination of two-
dimensional gel electrophoresis (2DE) and mass spectrometry (MS). Over the 
years, proteomics has expanded to include expression, functional, and structural 
proteomics based on a broad range of technologies. 
1.6.2.1 Expression proteomics  
Expression proteomics consists of identifying the protein present in a biological 
sample or the proteins that are differentially expressed between different samples. 
This approach is often used to make a list of proteins present in a sample and to 
discover proteins that are differentially expressed between different samples. In this 
strategy, global protein profiles are produced for normal compared with diseased 
cells, tissues, or for cells before and after treatment.  Currently, 2-DE is still the 
main workhorse for differential display of protein expression.  It is used to separate 
crude protein mixture into individual protein spots so that the global protein 
profiles of both the control and experimental samples can be compared for 
differentially expressed proteins(Freeman et al., 2004). Two-dimesional Difference 
gel electrophoresis (2-D DIGE) is an emerging technology that allows for accurate 
quantification with statistical confidence while controlling for non-biologic 
variation, and also increases the dynamic range and sensitivity of traditional 2D 
polyacrylamide gel electrophoresis. With inclusion of an internal standard formed 
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from equal amounts of every sample in an experiment, difference gel 
electrophoresis technology also allows for repetitive measurements and 
multivariable analyses to be quantitatively analyzed in one co-ordinated experiment, 
yielding statistically-significant changes in protein expression related to many 
disease states. This technique promises to be an important tool in clinical 
proteomics and the study of the mechanism of disease, investigating diagnostic 
biomarkers and pinpointing novel therapeutic targets. Table 1-3 shows the 









Table 1-3 Comparison of 2-DE and 2-D DIGE 
Note: 2-DE, two-dimensional electrophoresis; 2-D DIGE, two dimensional difference in gel electrophoresis; IEF, isoelectric focusing; SDS-PAGE, 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis; LC/LC, tandem liquid chromatography; PMF, peptide mass fingerprinting; (Modified from 
Freeman WM, Hemby SE. 2004) 
 2-DE 2-D DIGE 
Separation Electrophoresis, IEF, SDS-PAGE Electrophoresis, IEF, SDS-PAGE 
Quantification Densitometry of stains Imaging of Cy3 and Cy5 labeled proteins, normalized to Cy2 
Identification PMF PMF 
No. of proteins 100s to low 1000s 100s to low 1000s 
Hydrophobic 
proteins 
Moderate, dependent on detergent used Moderate, dependent on detergent used 
Low expressed 
proteins 
Marginal Moderate, need saturating labels 
Strength Low cost, comparably easy techniques High quality of quantification of multiple samples 
Limitations Limited quantification, difficulty of spot matching Require expensive dedicated instrument 
- 16 - 
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1.6.2.2 Functional proteomics 
Functional proteomics attempts to discover protein functions based on the presence 
of specific functional groups or based on their involvement in protein-ligand 
interactions, such as protein complexes. Proteins need to interact with other 
molecules to perform their roles. Clarification of the interactors of the proteins 
could help to discover their roles in the cell. Similarly, pathways can be defined as 
a cascade of specific protein interactions required to activate cellular functions. 
Posttranslational modifications, such as phosphorylation, define the activity, 
localization, and degradation of proteins and are keys to understanding the 
functions of proteins. In some ways, functional proteomics focuses on 
understanding part of the wiring diagram of a cell. 
1.6.2.2.1 Post-translational modification 
In order to perform the intrinsic functions, most proteins need to be post-
translationally modified. Therefore, the analysis of post-translational modification 
is important to determine the in vivo state of proteins. Various post-translational 
modifications such as removal of signal peptide, processing of precursor 
polypeptide, and modifications of amino acids have been reported. The 
modifications of amino acids are frequently detected by MS. In this case, the 
modified amino acid can be identified from the differences 
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(http://www.abrf.org/index.cfm/dm.home) between actual and theoretical 
molecular masses.  
Among various post-translational modifications, phosphorylation and glycosylation 
have been widely studied. Protein phosphorylation is closely related to signal 
transduction. The research field of the phosphoprotein in proteomics is called 
"phosphoproteomics". Glycosylation of proteins is related to the function such as 
cell recognition, membrane binding, enzymatic activity, interaction between 
proteins, etc. 
1.6.2.2.2 Protein-protein interaction 
Proteins function by interacting with other proteins and ligands. Analysis of 
protein–protein (ligand) interaction is important to determine the function of 
proteins. The analysis of protein–protein (ligand) interaction is called 
"interactome" analysis, and the scientific field is called "interaction proteomics". In 
proteome analysis, the interactions are often analyzed by immunoaffinity 
purification, surface plasmon resonance analysis (SPR) and MS. 
In immunoaffinity purification, epitope tagging and tandem affinity purification 
(TAP) are the two techniques used to detect protein–protein interaction. In epitope 
tagging, DNA which encodes the fusion protein of a target protein and epitope is 
over-expressed in the cell. The protein that interacted with the target protein is 
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purified by immunoprecipitation using an antibody, separated by electrophoresis 
and identified by MS. In the TAP method, the fusion protein where two epitopes 
(IgG binding domain of protein A and calmodulin binding peptide) are conjugated 
to the target protein is over-expressed, and the protein complex consisting of the 
target protein and the interacted proteins is purified by two steps of purification 
using IgG- and calmodulin-beads (Rigaut et al., 1999). This method is used to 
detect protein–protein interaction in many organisms. 
In surface plasmon resonance analysis (SPR), the interaction is analyzed using the 
phenomenon called surface plasmon resonance. Ligands such as proteins are 
immobilized on the sensor chip surface, and the sensor chip is installed in SPR 
spectrometer. The protein solution is applied into the flow cell. If the specific 
protein (analyte) binds to the ligand, the surface plasmon resonance signal changes. 
This change is measured by the photodiode array detector to detect the protein–
protein (ligand) interaction. In SPR, it is also possible to analyze the binding 
kinetics. The bound protein is digested in the flow cell with protease, and the 
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1.6.2.3 Structural proteomics 
Structural proteomics attempts to determine the tertiary structure of proteins, the 
structure of protein complexes and smallmolecule protein complexes. X-ray 
crystallography and nuclear magnetic resonance (NMR) spectroscope are its main 
methods (Staunton et al., 2003; Terwilliger 2003; Yee et al., 2003). Other 
approaches, such as homology modeling (Sanchez et al., 2000) and electron 
microscopy (Henderson 1995) will also become important tools in the near future 
since these methods could be complementary to NMR and X-ray crystallography in 
structural proteomics research. 
1.6.3 Proteomic study of HCC 
More accurate methods for the early detection of HCC are definitely needed. The 
poor prognosis of HCC is largely due to the lack of reliable early diagnosis. Cancer 
proteomics is aimed at identifying changes in protein expression, structure and 
posttranslational modification, as well as in subcellular localization. Some of the 
changes may correlate with the appearance of tumor. In addition, proteomics also 
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1.6.3.1 Strategies for biomarker discovery in HCC 
1.6.3.1.1 Direct analysis of serum and other biological fluids 
Because of the complexity and extraordinary dynamic range of serum, protein 
profiling is extremely challenging. Moreover, the most abundant proteins in serum, 
such as albumin, immuno globulins, transferrin, α-macroglobulin, antitrypsin and 
hepatoglobulin, account for >95% of total serum protein (Anderson et al., 2002). In 
serum, markers are expected to be in relatively low abundance. To overcome this 
difficulty, the most abundant proteins have to be removed from serum by such 
techniques as immunodepletion (Zolg et al., 2004). These techniques are only 
reliable assuming that the molecules of interest and potential targets are not bound 
to the major circulating protein. Alpha-fetoprotein (AFP) remained the gold 
standard for hepatocellular carcinoma scanning for forty years. Serum levels above 
the reference range of 10ng/mL occur in approximately 75% of cases of HCC. 
However, the specificity of AFP is relatively low because moderately raised levels 
are also found in some patients with chronic liver disease. (Johnson, 2001) Recent 
study showed that the human cervical cancer oncogene protein could act as the 
potential biomarker for diagnosis of early, small HCC, because it had higher 
sensitivity and speciality over AFP and was elevated according to disease 
progression from liver cirrhosis to carcinoma. (Yoon et al., 2004)  
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1.6.3.1.2 Analysis of the diseased tissue 
The candidate markers in tissue should be facilitated to identify by MS, because 
they presumably present at a higher concentration. However, to be clinically useful, 
the candidate markers also would have to be detectable in biological fluid. Most 
proteomics analysis of HCC tissue is performed using 2-D PAGE, followed by MS. 
This technique led to the identification of a large number of proteins modified in 
HCC compared with adjacent non-tumor tissue. So far, there were more than 200 
proteins identified in hepatocellular carcinoma tissue, and about 32 proteins were 
found up- or down-regulated with distribution to different subcellular locations  
(Kim et al. 2002, Kim et al,. 2003, Lim et al., 2002, Park et al., 2002). (See Figure 
1-2) Some proteins, such as sarcosine dehydrogenase, liver carboxylesterase, 
peptidyl- prolyl isomerase A, and lamin B1 were considered HCC marker 
candidates (Lim et al., 2002). Recently, Chung’s group conducted proteome 
analysis of the normal and tumor regions of resected human liver using two-
dimensional difference gel electrophoresis coupled with mass spectrometry. Three 
down-regulated metabolic enzymes, methionine adenosyltransferase, glycine N-
methyltransferase, and betaine-homocysteine S-methyltransferase that are involved 
in the methylation cycle in the liver were considered to relate to the spontaneous 
development of steatohepatitis and hepatocellular carcinoma. (Liang et al., 2005) 
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Figure 1-2 Subcellular localization of proteins up- or down-regulated in hepatocellular 
carcinoma (HCC), identified by means of 2-dimensional polyacrylamide gel 
electrophoresis and mass spectroscopy (2D-PAGE/MS). (Kim J., et al. 2002, Lim S.O., et 
al., 2002) 
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1.6.3.1.3 Host immune response as biosensor for cancer 
It has long been recognized that tumors expressed specific antigens. 
Conformational change and cellular accumulation of altered proteins can initiate an 
immune response and the generation of autoantibodies to these antigens. Therefore, 
the pool of circulating autoantibodies from the sera of patients with cancer contains 
the repertoire of antibodies elicited against the tumor. Proteomic approach relying 
on 2-D PAGE and MS has been implemented for the identification of tumor 
antigens that induce antibody response in HCC (Shalhoub et al., 2001, Le Naour et 
al., 2002). This approach allows the identification of auto-antibodies to proteins in 
lysates prepared from tumor and tumor cell lines and thus may more readily 
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1.6.3.1.4 Analysis of HCC cell lines 
For the possibility of infinite sample available and obvious advantage conferred by 
analysis of the homogeneous cell, HCC cell lines have been regarded as the ideal 
model to study the molecular basis of hepatocellular carcinogenesis as an initial 
step, or as useful tools in investigating the effect and mechanism of anticancer 
drugs. Proteomic analysis of all types of HCC cell lines, such as HepG2, HCC-M, 
etc, may provide new insights in HCC study. 
One of the earliest documented efforts are those by Wirth et al. who compared the 
two-dimensional electrophoresis (2-DE) maps of hepatic proteins between normal 
adult liver and two nontransformed, Chang and WRL-68, and four human 
hepatoma derived cell lines, HepG2, Huh-7, FOCUS and SK-Hep (Wirth et al., 
1995). Sanchez et al. also presented 2-DE maps of human liver, HepG2 cells and 
its secreted proteins (Sanchez et al., 1995). Subsequently, Yu et al. reported the 
identification of differentially expressed proteins between a human heptoma (BEL-
7404) and normal (L-02) liver cell lines (Yu et al. 2000). Some of these proteins, 
such as reticulocalbin, are demonstrated to be present in hepatoma cells for the first 
time, while adipocyte-type fatty acid-binding protein (A-FABP) had earlier been 
found to be associated with the progression of human bladder transitional cell 
carcinomas. This work has been reviewed by Seow et al. who compiled the known 
proteomic difference among the different liver cells examined, some inferred from 
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cDNA microarray analysis (Seow et al., 2001)  
To date, the most comprehensive proteomics effort dedicated to a selected HCC 
cell line is that undertaken by Chung’s group who focused on HCC-M cells. At the 
last count, from a total of 408 unique spots excised from the 2-DE gel, a total of 
about 191 different proteins were identified and grouped into different functional 
categories, accessible through their public web site. A separate reference list of 
identified proteins which have been implicated in HCC and other types of cancer is 
also provided (Seow et al., 2000; Liang et al., 2002).  
Lee et al. established an expression map of the most abundant proteins in HepG2 
cells by a combination of complementary shotgun proteomics approaches, in which 
a total of 247 proteins were identified. The combination of 1DE LC MS/MS, 2DE 
LC MS/MS and 1D MALDI-TOF MS/MS increased the sequence coverage and 
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1.6.3.2 Proteomics for discovery of therapeutic targets 
The challenge of elucidating the link between drug response and resistance, and 
then integrating the information for the purpose of therapeutic intervention, is a 
major task that awaits scientists in the post-genomic era. Rapid advances in 
proteome technologies have made it possible to simultaneously identify multiple 
proteins involved in drug refractory cancers. This methodology has the potential to 
isolate novel proteins, including those associated with resistance to specific drugs 
and those involved in conferring broad resistance to a range of compounds. The 
identification of key proteins will lead to the possibility of developing molecular, 
biological or pharmaceutical strategies to modify the action of such proteins when 
their inappropriate structure or expression is contributing to drug-resistant disease. 
Cancer cell culture models are suited for applying proteomics techniques, such as 
two-dimensional gel electrophoresis (2-DE) and mass spectrometry, to identify 
specific protein expression profiles and/or proteins that may be associated with a 
defined phenotype of the cancer cells, and then study mechanisms that lead to the 
development of therapeutic targets towards individual cytostatic drugs. For 
example, the effect of butyrate on HCC cell lines has been noticed for more than 
two decades. Some associated proteins, such as cholesteryl-ester-transfer protein 
(CETP), Glutaminase, cadherin and glutamyltransferase (GGT) were found to be 
differentially regulated in HCC cell lines under the treatment of butyrate (Bernhard 
et al., 1993; Barrie et al., 1994; Tetsuya et al., 2000; Daubeuf et al., 2001). Recent 
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publication showed that butyrate could induce apoptosis in HuH-6 and HepG2 by a 
mitochondria/caspase pathway, associated with degradation of beta-catenin, pRb 
and Bcl-XL. (Emanuele et al., 2004) These studies provided useful clues to 
understand the cell events of HCC under the treatment of butyrate. However, they 
all focused on single or just a few proteins. More molecules need to be elucidated 
to link all these protein as the signal pathway or even network of HCC cell arrest 
and apoptosis caused by butyrate. Without the context, the value of these proteins 
as therapeutic targets can not be estimated. Proteomic study possesses the ability to 
observe global protein expression alteration in a cell, tissue or organ, which may 
facilitate the achievement of signal pathway and detection of therapeutic targets. 
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1.7 Objective of our study 
Butyrate as a potent differentiation and apoptosis inducer has been proved to 
inhibit proliferation of HCC cells in vitro and in vivo. Some associated proteins 
were also found to be differentially regulated in HCC cell lines under the treatment 
of butyrate. These proteins provided useful clues. However, there is no proteomic 
study on the effect of butyrate on HCC cells so far. The advantage of proteomics in 
large range scanning was not taken in the field. Thus, we are applying proteomics 
technique to the study of some specific HCC cell lines under the butyrate treatment. 
This will lead to better understanding of the mechanism in HCC response to 
butyrate and possible discovery of novel molecular target. 
This project is focused on the response of two hepatoma cell lines: HCC-M and 
HepG2, to the treatment of butyrate. This effect was monitored by the change in 
protein expression using a 2D DIGE proteomics approach.   
The objective of our study is twofold.  Firstly, we want to examine if the two cell 
lines, which are of the same histological type but different origin, possess distinct 
response under the same butyrate treatment and growth conditions. Secondly, we 
hope find the proteins which can help to explain the different response of two cell 
lines to butyrate we observed and even provide new possibility of understanding 
the mechanism of development and therapy of HCC. Due to the unbiased discovery 
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nature of proteomics approach, novel molecular targets involved in HCC 


















Materials and Methods 
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2.1  Materials 
 
Analytical grade reagents were used for the preparations of general reagents.  Special 
reagents were obtained from: 
 
Amersham Pharmacia Biotech (Sweden) 
Agarose (USB) 
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) 
Immobilized pH gradient (IPG) strips 
pH 3-10 IPG buffer (non-linear) 
 
Bio-Rad Laboratories (U.S.A.) 
40% acrylamide/ bis solution in 37.5: 1 ratio 
Ammonium persulfate (APS) 
Dithiothreitol (DTT) 
EDTA disodium dihydrate 
Polyacrylamide gel reagents 
















Sodium dodecyl sulphate (SDS) 
 




EM Science (U.S.A.) 
Acetonitrile 
 





Modified porcine trypsin 
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PIERCE (Rockford, Bedford, MA, USA) 
Coomassie® Plus Protein Assay 
 
J.T.Baker (U.S.A.) 
Tris(hydroxymethyl) aminomethane (Tris) 
 
Sigma Chemical Co. Ltd. (U.S.A.) 
n-Butyric acid sodium salt 
Dulbecco’s Modified Eagle’s media 
Ammonium carbonate 
Coomassie Blue R-250 
Ethylenediaminetetraacetic acid (EDTA) 
Phenylmethyl sulfonyl fluoride (PMSF) 
Trifluoroacetic acid (TFA) 
All common laboratory chemicals 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
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2.2 Cell culture 
2.2.1 Cell lines 
HCC-M was obtained from Bioprocessing Technology Institute (BTI), while HepG2 was 
kindly provided by Dr. Terasa Tan. 
2.2.2 Preparation of cell culture media 
Table 2-1   Composition of complete  Dulbecco’s Modified Eagle’s media 
 Stock concentration Volume added 
Final 
concentration 
DMEM media  450 ml  
Pen/strep 100x 5 ml 1x 
Sodium Pyruvate 100mM 5ml 1mM 
Non-essential 
amino acid 10mM 5ml 0.1mM 
FBS* 100% 50ml 10% 
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2.2.3 Thawing of frozen cell stock 
The prepared complete DMEM was pre-warmed in 37℃ water bath. 12ml DMEM 
was pipetted into the T75 flask, and this volume of solution was sufficient for 
covering the whole of flask surface. Ampoules were transferred directly to a 37℃ 
water bath until the contents were thawed with the cap non-submerged in order to 
prevent contaminated water from entering the ampoules. The ampoules were then 
sterilized using 70% alcohol and transferred into the hood. The ampoule content 
(1-2ml) was transferred directly and gently into the flask containing the pre-
warmed growth medium (12 ml). This time the cell number is about 107. The flask 
was then transferred into the incubator with the cap slightly loosened. Growth 
medium was changed after 24h. 
2.2.4     Cell passage  
The medium was removed completely, and the attached cells were gently rinsed 
with 3ml (for T75) of sterilized PBS once. The flask surface was covered with 1ml 
of trypsin and incubated in 37 ℃for 3-4min until the cells were detached. 1ml 
DMEM containing 10% FBS was added to stop the digestion. The mixture was 
resuspended several times to achieve the single-cell suspension. 1/10 of the cell 
suspension was transferred into the T75 flasks which contained 12ml of DMEM 
medium respectively. This was kept in the incubator. 
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2.3   Assessment of cell viability by MTT quantitative colorimetric assay 
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is 
based on the ability of a mitochondrial dehydrogenase enzyme from viable cells to 
cleave the tetrazolium rings of the pale yellow MTT and form a dark blue formazan 
crystals which is largely impermeable to cell membranes, thus resulting in its 
accumulation within healthy cells. Solubilization of the cells by the addition of a 
detergent resulted in the liberation of the crystals which were solubilized. The 
number of surviving cells is directly proportional to the level of the formazan 
product created (Mosmann T, 1983). The results can be read on a multi-well 
scanning spectrophotometer. 
Cells were seeded on 6-wells plates after cell counting (3,000/well), and allowed to 
adhere overnight. Then cells were treated with butyrate at a concentration of 1mM, 
2mM, 5mM, 10mM, 20mM and 30mM for 12, 24, 48, 72, 96 and 120hours, 
respectively. The cell growth was measured by the MTT reagent uptake procedure. 
After two-hour of incubation, the medium-MTT reagent mixture was removed and 
0.5ml of DMSO was added. The solution was mixed well for several times. 0.1ml 
of the solution was transferred to a 96-well microtitre plate. The absorbance was 
read at 550nm using Spectra MAX 190 (Molecular Devices Corporation; 
Sunnyvale, California, U.S.A.) spectrophotometer. Statistical analysis were carried 
out with SPSS 10.0 
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2.4  Quantitative analysis of apoptosis 
Annexin-V-FLUOS kit (Roche Diagnostic GmbH; Mannheim, Germany) was used 
to test the apoptotic percentage of the treated cells. Annexin V is a phospholipid-
binding protein with a high affinity for phosphatidylserine (PS). Detection of cell-
surface PS with annexin V thus serves as a marker for apoptotic cells. Analysis 
may be by flow cytometry or by fluorescence microscopy. Annexin-V-FLUOS 
(green dye) serves as a fluorescent probe for apoptotic cells. They will not bind 
normal, intact cells. However, since necrotic cells are leaky enough to give 
Annexin-V-FLUOS access to inner membrane PS, apoptotic cells have to be 
differentiated from necrotic cells. Thus, the assay involves simultaneous staining 
with both Annexin-V-FLUOS and the DNA stain propidium iodide. Exclusion of 
propidium iodide coupled with binding of Annexin-V-FLUOS indicates an 
apoptotic cell. 
Table 2-2 Distinguishing apoptosis using Annexin-V. 
 Normal cells Apoptotic cells Necrotic cells 
Annexin-V staining 
- + + 
Propidium iodide 
staining - - + 
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Cells were seeded on 6-wells plates after cell counting (30,000/well), and allowed 
to adhere overnight. Then cells were treated with butyrate at a concentration of 
5mM for 12hours, 24hours, 36hours, 48hours and 72hours, respectively. 2.5ml of 
incubation buffer with 50μl Annexin V and 50μl Propidium iodide (PI) was added 
to the cell pellet. The suspension was shaken and warmed to room temperature, and 
finally mixed with 100μl of staining solution. The cell suspension was singularized, 
before flow cytometric analysis was performed. Statistical analysis was made with 
SPSS 10.0 
2.5 Harvest of cells 
The medium (contains some floating cells) was transferred into centrifuge tube (sit 
in ice), then 2 ml PBS was added into the flask to rinse cells. Trypsin was added in 
to trypsinize cells at 37℃. 1ml media was added to neutralize the trypsin. Detached 
cells were transferred into a 50ml tube. The flask was rinsed with 3 ml of PBS to 
ensure complete removal of cells from the flask. The tubes were centrifuged at 
300g  for 5 min at 4℃ to pellet the cells. After the supernatant was removed, PBS 
(10 times the volume of the cell pellet) was added in to rinse the cells. Cells were 
spun down, and PBS was removed. The step of PBS rinsing was repeated for 
another two times. Cells were re-suspended in 1ml PBS and transferred into a new 
1.5 ml microfuge tube. The cells in the tube were spun down at 300g for 5min. 
Supernatant was removed.  
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2.6   Preparation of cell lysate for 2-dimesional electrophoresis 
Harvested cells were solubilized with a cocktail of 7M urea , 2M thiourea, 4% w/v 
3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), 40mM 
tris (hydroxymethyl) aminomethane (Tris), and 1% w/v protein inhibitor cocktail . 
50μg/ml DNase I and 50μg/ml RNase A was added to the resulted cell lysate. The 
solution was then centrifuged at 15,000g for 1 hour at 10℃using a Beckman 
coulter TM Microfuge ( Palo Alto, CA, USA). The supernatant was kept and its pH 
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2.6.1 Preparation of lysis buffer 
Lysis buffer was prepared as follows:  
Table 2-3 Composition of lysis buffer for 2-D gels 
Buffer components Amount/Volume added Concentration 
Urea 21.021 g 7 M 
Thiourea 7.612 g 2 M 
CHAPS 2.0 g 4% w/v 
Tris-base 0.2422 g 40 mM 
H2O Up to 50 ml - 
Note: Aliquots of 1 ml each were transferred to an Eppendorf tube and stored at -20°C.   
 
 
2.7    Protein estimation 
Protein concentration was estimated using the Coomassie® Plus assay kit.  Protein 
sample were diluted to keep the concentration of urea and thiourea within 
acceptable range of the assay. Concentration of protein was estimated by 
measuring the adsorbance at 595 nm using bovine serum albumin (BSA) to 
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2.8  Two-dimensional difference gel electrophoresis  
The technique of two-dimensional difference gel electrophoresis (2-D DIGE) is 
based on Ettan DIGE system (Amersham Pharmacia Biotech, Sweden). The system 
is based on the specific properties of the three CyDye DIGE Fluor minimal dyes 
which permit multiplexing of up to three separate protein mixtures on the same 2-D 
gel. The major benefit of Ettan DIGE system is that multiplexing contains the same 
internal standard on every 2-D gel, which gives confidence that the results can 
reflect true biological difference and are not due to the system i.e., experimental 
variation.  
Ettan DIGE system comprises CyDye DIGE Fluor minimal dyes, Typhoon 
Variable Mode Imager and DeCyder Differential Analysis Software. The dyes have 
high sensitivity with detection down to 125pg of a single protein, and a linear 
response to protein concentration up to five orders of magnitude (105). DeCyder 
Differential Analysis Software can perform co-detection of differently labeled 
samples within the same gel. DeCyder Differential Analysis Software also permits 
automated detection, background subtraction, quantitation, normalization, internal 
standardization and inter-gel matching. The benefits are low user interaction, high 
throughput and low experimental variation. The brief protocol is shown as Figure 
2-1. 





Figure 2-1. Outline of Ettan DIGE system (when used with three CyDye DIGEFluor minimal dyes separated in a single 
gel). (Taken from Ettan DIGE system user manual) C
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2.8.1 Protein sample labeling  
Protein samples were labeled using the CyDye DIGE Fluor, minimal labeling kit 
(Amersham Pharmacia Biotech, Sweden). Stock solution of CyDye Fluor was 
diluted by dimethylformamide to 400pmol/μl. Aliquot of protein sample (25μg) 
was labeled with 200 ρmol of dye for the labeling reaction. Three separate 
batches of samples were used in this experiment and duplicate gels were run for 
each batch (see Table 2-4). The control sample was labeled with Cy3, treated 
sample with Cy5 and the pooled standard, which consists of the control and 
treated samples in equal portions, was labeled with Cy2. The dye and protein 
sample were mixed thoroughly by vortexing and centrifuged briefly in a 
microcentrifuge. The mixture was left on ice for 30 min in the dark. 1 µl of 
10mM lysine was added to stop the reaction. The solution was mixed and spin 
briefly in a microcentrifuge, and left on ice again for 10 min in the dark. The 
labeled samples can be processed immediately or stored for at least 3 months at  
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Table 2-4   Experimental plan for 2-D DIGE.  
Batch No. Gel No. Cy2 Standard Cy3 Control Cy5 Treated 
1 1 C1-3,T1-3 C1 T1 
 2 C1-3,T1-3 C1 T1 
2 3 C1-3,T1-3 C2 T2 
 4 C1-3,T1-3 C2 T2 
3 5 C1-3,T1-3 C3 T3 
 6 C1-3,T1-3 C3 T3 
Note: The plan was applied to both HepG2 and HCC-M cells. C1, C2 and C3 were 
control samples. T1,T2 and T3 were treated samples with 24h 5mM butyrate treatment. 




2.8.2 Two-dimensional gel electrophoresis (2-DE) 
All the operations using labeled samples were performed in the dark. 
2.8.2.1 First dimension - isoelectric focusing (IEF) 
2.8.2.1.1 Active rehydration of IPG strips 
For rehydration, precast 18 cm, pH 3-10 non-linear, dry immobilized pH 
gradient strips (IPGs) were immersed overnight in a rehydration buffer 
containing 7 M urea, 2 M thiourea, 4% CHAPS, 20 mM DTT and 5% IPG buffer 
(pH 3-10).   
Chapter II 
  - 46 -
This process was first performed by pipetting 340 μL of the rehydration buffer 
including labeled sample into the ceramic strip holders.  Then, the protective 
plastic layer of the IPG gel was removed and the IPG gel was placed onto the 
strip holder with the gel-coated surface facing down, so that the gel surface was 
in contact with the rehydration buffer.  To prevent uneven rehydration, trapped 
air bubbles were smoothened carefully with a clean needle. This is followed by 
covering the gel with a layer of paraffin oil and a plastic cover so as to prevent 
exposure of the rehydration buffer to air.  This is important because 
crystallization of the highly concentrated urea might occur due to evaporation of 
the buffer.  Active rehydration was set as 30V for 7hours and 60V for 7hours. 
2.8.2.1.2 Preparation of rehydration buffer 
Table 2-5 Composition of rehydration buffer for IPG strips 
Buffer components Amount/Volume added Concentration 
Urea 21.021 g 7 M 
Thiourea 7.612 g 2 M 
CHAPS 2.0 g 4% w/v 
Bromephenol blue Trace - 
H2O Up to 50 ml - 
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2.8.2.1.3 Isoelectric focusing (IEF) 
All IEF experiments were performed with Amersham Pharmacia IPGphor 
machines. IEF was conducted with the following steps:  
Table 2-6 Voltage gradient applied for isoelectric focusing 
Steps Voltages (V) Mode Volt-Hours (V-hr) 
1. 200 Step and hold 200 
2. 500 Step and hold 500 
3. 1000 Step and hold 500 
4. 1000-8000 Gradient 2250 
5. 8000 Step and hold 36000 
Note: Upon completion, the IPG strips were recovered, kept in a Pyrex glass tube and 
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2.8.2.2        Second dimension 
2.8.2.2.1     Equilibration of IPG strips with SDS equilibration buffer 
Before the strip was transferred to the second dimensional polyacrylamide gel, it 
is necessary to equilibrate the IPG strips in 2 steps. The first step involved 
reduction of the disulphide bonds.  Gel strips were placed in an equilibration 
buffer consisting of 6 M urea, 30% glycerol, 2% SDS, 50 mM Tris-HCl (pH 6.8) 
and 1% (w/v) DTT and shaken slowly on a rocker for 15 minutes.  This 
equilibration step was required because it reduced the disulphide bonds and 
conditioned the IPG strips with the SDS buffer system required for the second 
dimensional separation.       
This was followed by the alkylation step whereby the equilibration buffer was 
discarded and replenished with a fresh batch of equilibration buffer made of 6 M 
urea, 30% glycerol, 2% SDS, 50 mM Tris-HCl (pH 8.8), and 2.5 % (w/v) 
iodoacetamide (IAA).  This step allowed the free thiol groups of cysteines to be 
alkylated so as to prevent reoxidation.  This additional step replaced the 
reductant with iodoacetamide. 
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2.8.2.2.2   Preparation of SDS equilibration buffers 
The equilibration buffer is prepared as follows: 
Table 2-7 Composition of buffer used for equilibration of IPG strips  
Stock Solutions pH 6.8 buffer 
Amount/volume 




Tris-HCl (pH 6.8, 1.0 M) 50 ml - 50mM 
Tris-HCl (pH 8.8, 1.5 M) - 33.33 ml 50mM 
Urea 360.63 g 360.63 g 6 M 
Glycerol 300 ml 300 ml 30% 
SDS 20 g 20 g 2% 
Bromophenol blue trace trace - 
H2O Top up to 1 L Top up to 1 L  
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2.8.2.2.3   Sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
SDS-PAGE is a rapid method for protein separation, quantification, and 
characterization.  SDS, being an ionic detergent, binds to proteins at a uniform 
negative charge density and denatures them.  Thus, SDS-bound polypeptide is 
separated in the gel according to its molecular weight alone.  SDS-PAGE with 
the tris-glycine system was chosen as the second dimension for its unsurpassed 
resolution and ease of use.  12.5% polyacrylamide gels were cast based on the 
following recipe:  
Table 2-8 Composition of SDS-PAGE used for second dimensional separation  
Stock solution Volume (ml) 
40% acrylamide/ bis solution in 37.5: 1 ratio 75 
1.5 M Tris-HCl, pH 8.8 60 
Deionized water 100.08 
10% SDS 2.4 
10% APS 2.4 
TEMED 0.12 
Total  240 
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2.8.2.2.4 Preparation of sample loading buffer   
Protein samples were denatured before SDS-PAGE.  This was accomplished by 
dissolving protein samples in the sample loading buffer.  2x sample loading 
buffer was used for liquid sample and is prepared according to the table below.  
Aliquots of 1 ml each were transferred to Eppendorf tubes and stored in freezer 
at -20°C.   
Table 2-9 Composition of sample loading buffer for SDS-PAGE  
Ingredients Volume (mL) 
MilliQ Water 1.3 
1.0 M Tris-Cl pH 6.8 1.2 
Glycerol 2 
10% (w/v) SDS 4 
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2.8.2.2.5 Preparation of electrode buffer 
Tris-glycine buffer was the electrode buffer used in our SDS-PAGE experiments.  
It was prepared as follows: 
Table 2-10 Composition of electrode buffer used for SDS-PAGE  
Ingredients Amount/Volume 
Tris 15g  
Glycine 72 g 
1.0 g of SDS 5 g  
MilliQ water Top up to 5 L 
 
2.8.2.2.6 Molecular weight standards 
Broad range standard molecular weight markers (Bio-Rad) used included rabbit 
skeletal muscle myosin (200 000 Da), E. Coli beta galactosidase (116, 250 Da), 
rabbit muscle phosphorylase b (97 000 Da), bovine serum albumin (66 200 Da), 
hen egg white ovalbumin (45 000 Da), bovine carbonic anhydrase (31 000 Da), 
soybean trypsin inhibitor (21 500 Da) and hen egg white lysozyme (14 400 Da) 
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2.8.2.2.7 Treatment of protein molecular weight markers 
Molecular weight markers were mixed with 2x SDS sample loading buffer at a 
ratio of 1:1 and then heated at 95°C for 5 min prior to application.  About 5 μl of 
this mixture was dispensed carefully onto a piece paper application strip before 
being transferred to the second dimension.  
2.8.2.2.8 Transfer of IPG strip to the second dimension 
After SDS equilibration, the IPG strip was rinsed in purified water and blotted 
dry before being transferred to the second dimension by gently laying the strip 
on top of a SDS gel.  Protein molecular weight markers loaded on a piece of 
application strip was inserted at one end of the strip.  This is followed by gently 
dispensing 0.75% agarose to seal the IPG strip and the paper strip to the second 
dimension.   
2.8.2.2.9   SDS-PAGE running conditions 
The second dimensional gel was performed using a Bio-Rad Protean IIxi cell gel 
set with the power pack set at a constant current of 15mA per gel for 20 minutes 
and then 30mA per gel. The system was cooled to 10°C with a water circulator 
(Colora Messtechnik GMBH Lorch/Wurtt, Germany). 
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2.8.3 DIGE gel image acquisition by Typhoon Variable Mode Imager 
The protocol followed the instruction provided by the manual. Optimal 
excitation/emission wavelength for each DIGE fluor was Cy2, 488/520 nm; Cy3, 
532/580 nm; Cy5, 633/670 nm. The images were viewed in the ImageQuant 
software (Amersham Biosciences). 
2.8.3.1   DIGE gel image analysis by DeCyder Differential Analysis Software  
This analysis involves the following steps:  
z Running a series of four sequential DIA analyses (for each of the six gels).  
z Performing spot detection and calculation of the spot properties. Enter the 
value 5000 for the estimated number of spots. 
z Removing non-protein spots using the previously ascertained exclusion 
filter parameters.  
z Normalization of the protein spots using the in-gel linked internal standard.  
z Loading of the derived spot maps and associated data into the BVA module.  
z Inter-gel matching of spot maps.  
z T-test analysis of proteins in control and treated samples. Significant spots 
should be the ones with average alteration ratio more than 1.5 and P value of 
t-test less than 0.05. 
z Generation of a pick list for later protein identification. 
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2.9   Gel image visualization by silver staining 
To detect and visualize any protein spots, the 2-D gels will need to be stained.  
In our case, we used silver staining.  After gel electrophoresis, the transparent 
gels were recovered and immediately kept in fixing solution prior to staining to 
visualize protein spots.  Silver staining was performed according to Shenchenko 
et al. (Shenchenko et al., 1996).  Silver stain can detect up to nanogram of 
proteins and hence is suitable for staining 2-D gels. 
2.9.1 Silver staining procedure 
2-D gels were first immersed in fixing solution for 30 min before washing with 
50% methanol in water for another 30 min.  Then, the gels were washed again 
with water for 60 min followed by sensitization with 0.02% sodium thiosulphate 
for 2 min.  After the gels were rinsed with water twice for 2 min each, they were 
incubated with chilled 0.1% w/v silver nitrate for 40 min at 4°C.  After 
discarding the silver nitrate and rinsing with 2 changes of water for 1 min each, 
the gels were developed in 0.04% formalin (35% formaldehyde in water) in 2% 
sodium bicarbonate. When the desired image intensity is attained, the developing 
solution was discarded and the gel incubated with 1.46% EDTA disodium 
dihydrate for 10 min to stop the development.  The silver stain procedure was 
completed with 3 rinses of water for 5 min each. 
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2.9.2   Preparation of silver stain reagents 
Reagents for silver stain were prepared as follows: 
Table 2-11 Composition of reagents used in silver stain 
Solutions Ingredients Composition 
 methanol 2.5 L (50%) 
Fixing Solution acetic acid 250 mL (5%) 
 MilliQ water 2.25 L 
 TOTAL 5 L 
 Methanol 2.5 L 
50% Methanol MilliiQ water 2.5 L 
 TOTAL 5 L 
 sodium thiosulphate 1 g 
Sodium Thiosulphate MilliQ water Top up to 5 L 
 Silver Nitrate 2.5 g (0.1%) 
Silver Nitrate MilliiQ water Top up to 2.5 L 
 sodium carbonate 100 g (2%) 
Developing Solution formalin 0.04% 
 MilliiQ water Top up to 5 L 
 EDTA-Na2.H2O 73 g 
Stop Solution MilliiQ water Top up to 5 L 
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2.10 Identification of protein spots 
Identification of protein spots of interest was performed using matrix assisted 
laser desorption/ionization – time of flight mass spectrometry (MALDI-TOF 
MS).  First, the proteins spots were excised and digested with trypsin.  The 
peptides were then extracted from the gel pieces and subject to mass-
spectrometric analysis. 
2.10.1 Excision of protein spots 
The protein spots of interest were excised manually with trimmed plastic pipette 
tips and transferred to 0.6ml eppendorf tubes. To avoid contamination from 
keratin, a new pair of gloves was worn each time when performing trypsin digest. 
Each excised spot was washed with 150μl of washing buffer (2.5mM ammonium 
bicarbonate (NH4HCO3), 50% acetonitrile).  The tubes were sealed with an 
adhesive film and stored at 4°C for at least 24 hours.  Alternatively, the excised 
spots can be washed with 150μl of 2.5mM ammonium bicarbonate (NH4HCO3), 
in 50% acetonitrile for 3 times of 20 min each.  This washing step was critical as 
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2.10.2 Reduction and alkylation of excised protein spots 
The solution was replaced with 150μl of fresh washing buffer and tubes were 
incubated with shaking for 10 min at 37°C.  The washing solution was then 
aspirated and gel spots were dried in a SpeedVac (eppendorf Concentrator 5301, 
Germany) for 20 minutes. The gel spots were reswollen in 20μl of solution 
containing 10mM DTT/100mM NH4HCO3 and incubated at 56°C for 1 hour. 
The solution was subsequently replaced with 20μl of solution containing 55mM 
IAA/100mM NH4HCO3 and incubated in the dark, at room temperature for 45 
min, with occasional vortex.   
Then, the liquid phase was aspirated and the gel was then washed in 100μl of 
100mM NH4HCO3 solution for 10 min.  Subsequently, the solution was removed 
and the gels were dehydrated in 100μl of 100% acetonitrile for 10 min, again.  
The above wash and dehydration steps were repeated for three times.  Finally, 
the batch of solution was removed and gel spots were dried in a SpeedVac.   
2.10.3 In-gel trypsin digestion 
After reduction and alkylation, the excised gel spots were each digested with 
10μl of 0.02μg/μl sequencing grade modified porcine trypsin in 25mM 
NH4HCO3, pH 8.5 and incubated at 37°C overnight with shaking.  
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2.10.4 Extraction of peptides from gels 
To extract trypsin-digested peptides from the gel plug, 10μl of 0.1% 
trifluoroacetic acid (TFA) in 50% acetonitrile was added to each tube followed 
by  sonication for 20 min in an ultrasonic water bath (Branson 2200, Branson 
Cleaning Equipment Company, Shelton, CT, U.S.A).  The resulting solution 
containing peptides from proteins of interest was concentrated to less than 1μl 
using a SpeedVac, and was used for mass determination with a MALDI-TOF 
MS. 
2.10.5  Preparation of matrix solution 
A matrix is a small organic acid used to co-crystallize with the extracted 
peptides.  The laser energy from the laser source of the MALDI-TOF MS was 
transferred to the matrix-coated peptide.  The matrix was prepared by dissolving 
10 mg of α-cyano-hydroxycinnamic acid in 1 ml 0.1% TFA/50% acetonitrile, 
and then mixed with 0.3mg/ml ammonium citrate 
2.10.6 Application of matrix and peptide samples 
0.5μL of extracted peptide sample was spotted onto a stainless steel MALDI 
sample plate followed by 0.5μL of matrix solution.  Samples were left to air-dry 
for subsequent MS analysis. 
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2.10.7 Mass spectrometry 
Peptides were analyzed on a MALDI-TOF Voyager-DE STR mass spectrometer 
from PerSeptive Biosystems operated on delayed extraction and reflector mode 
(Applied Biosystems, Framingham, MA, USA).  Spectra were acquired 
manually with laser intensity set at 2400, 50 shots per spectrum and a mass 
range of m/z 700 to m/z 3000. All spectra were calibrated internally using two 
trypsin autodigest ions (m/z 842.51, m/z 2211.104). 
Protein spots that did not give a confident match or with unidentified ions were 
further analyzed on the Applied Biosystems 4700 Proteomics Analyzer 
(MALDI-TOF/TOF). MS data were automatically acquired with a trypsin 
autodigest exclusion list and the five most intense ions selected for MS/MS. The 
collision gas was atmospheric air and the energy was 1 kV. Interpretation was 
carried out using the GPS Explorer software (Applied Biosystems) and database 
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2.10.8 Database searching and identification of proteins 
Database search was performed using the MS-Fit software (http:// 
prospector.ucsf.edu/ucsfhtml4.0/msfit.htm, Protein Prospector, UCSF, San 
Francisco, CA, USA) using the following parameters: carbamidomethylation of 
cysteine, all species, all Mr and pI, minimum of four peptides required to match, 
mass tolerance of 50 ppm, methionine oxidation, N-terminus acetylation, 
acrylamide modified cysteine and phosphorylation at serine, threonine and 
tyrosine. The Swiss-Prot nonredundant database was queried first, followed by 
the NCBI database, if no significant protein matches were found. 
Both combined MS-MS/MS and MS/MS only searches were conducted with the 
following settings: MSDB database (http://csc-fserve.hh.med.ic.ac.uk/msdb.htm), 
all entries, peptide tolerance at 200 ppm, MS/MS tolerance at 0.3 Da, 
carbamidomethylation of cysteine (fixed modification), phosphorylation at 
serine, threonine and tyrosine (variable modifications), methionine oxidation 
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 2.11 2-DE western blot 
2.11.1 2-DE using 7cm IPG strip 
30μg of protein lysate from treated HCC-M cells was loaded into 7cm pH 3-10, 
non-linear IPG strip. The process of active rehydration was as described in 
2.8.2.1.1.IEF was carried out using the following parameters: (i) 200V, 100Vh; 
(ii) 500V, 250Vh; (iii) 1000V, 500Vh; (iv) 1000V~8000V, 2250Vh; (v) 8000V, 
15000Vh. Voltage increases were performed on a “step-wise” basis. The strip 
was then subjected to a two-step equilibration in DTT (Bio-Rad) and IAA 
(Sigma) buffers for 15min each before proceeding to second dimension SDS-
PAGE. SDS-PAGE was performed on 1.0mm thick 12.5% polyacrylamide gel at 
a constant crrent of 15mA at 10℃ using Bio-Rad mini PROTEAN 3 cell gel set. 
2.11.2 Protein transferring 
After electrophoresis, the gel was equilibrated in transfer buffer (Tris 3.03g/L, 
Glycin 14.4g/L, Methanol 20%) for 10min and proteins were transferred onto 
polyvinylidene difluoride (PVDF) membrane (0.45μm) in transfer buffer for 
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2.11.3 Western blot 
PVDF membrane was then rinsed and blocked for 1 hour in TBS-T buffer (Tris 
10mM, NaCl 150mM, Tween-20 0.05%, pH 7.4) and 5% advanced ECL 
blocking powder (Amersham) at room temperature. Buffer was replaced with 
TBS-T containing primary antibody (chicken Affi-anti-RGS19IP1 IgY: 1:1000 
dilution in TBS-T in 1% advanced ECL blocking powder) and incubated for 1 
hour at room temperature. Following 3 washes in TBS-T, the blot was incubated 
for another hour at room temperature in TBS-T containing secondary antibody 
(goat-anti-chicken IgY conjugated-horse radish peroxidase: 1:10000 dilution in 
TBS-T in 1% advanced ECL blocking powder). The blot was then washed again 
for three times with TBS-T and soaked in advanced ECL Plus reagent 
(Amersham) for 15 seconds. Membrane was then exposed to Kodak Biomax MS 
film (Kodak, Rochester, NY). The primary antibody was from GenWay Biotech 
(GenWay, San Diego, CA), and the secondary antibody was from Santa Cruz 
Biotechnology (Santa Cruz, California) 
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3.1 MTT assay  
3.1.1 MTT assay of HepG2 
Cell treated with varying doses of butyrate from 0-30mM showed similar 
viability up to a time point of 24hour as compared to the non-treated control. 
From 24 hours onwards, the inhibition of growth rate was concentration 
dependent. Cell treated with 1 and 2mM butyrate exhibited minimal growth 
inhibition as compared to the non-treated control. The growth inhibition was 
further enhanced with 5mM butyrate treatment. Butyrate treatment at 10mM 
and above completely blocked the cell proliferation. (Figure 3-1) 
Figure 3-1 MTT assay result of HepG2 cells 
Note: SB is sodium butyrate. Different concentrations of butyrate from 0 to 30mM 
were denoted by different colors. * indicates there is significant difference between 
treated group and control group (SB-0mM) (P<0.05) 
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3.1.2 MTT assay of HCC-M 
Up to 24 hours treatment, cells under each concentration of butyrate (Figure 
3-2) showed similar viability. After 24hours, 1 and 2mM butyrate inhibited the 
cell growth in dose-dependent way. Cells treated with of 5, 10, 20 and 30mM 
could not proliferate at all. (Figure 3-2) 
 
Figure 3-2 MTT assay result of HCC-M cells 
Note: SB is sodium butyrate. Different concentrations of butyrate from 0 to 30mM 
were denoted by different colors. * indicates there is significant difference between 
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3.1.3 Comparison between the viability of HepG2 and HCC-M cells 
Butyrate could inhibit both cell lines’ viabilities in a dose and time-dependent 
manner. For HCC-M, low concentration (1 and 2mM) of butyrate could slow 
down the cell growth rate, and when the concentration increased to 5mM, the 
cell proliferation was completely inhibited. As for HepG2, low levels sodium 
butyrate (1 and 2mM) seemed to have no obvious influence on cell 
proliferation, but at 5mM it showed partial inhibition, and complete inhibition 
at 10mM. 
Thus, at a concentration of 5mM butyrate, the two cell lines showed an 
obvious difference in the inhibition of cell growth (Figure 3-3). The statistical 
analysis showed that the difference is significant (P<0.05). 
 
Figure 3-3 Comparison of the viability between HepG2 and HCC-M cells after the 
treatment with 5mM butyrate 
Note: * indicates there is significant difference between treated group and control 
group (SB-0mM) (P<0.05); # indicates there is significant difference between HepG2 
treated group and HCC-M treated group (P<0.05) 
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3.2 Quantitative apoptotic assay  
3.2.1 Apoptotic assay of HepG2 
Apoptosis was measured by membrane externalization of phosphatidylserine. 
Untreated HepG2 cells showed a low basal level of apoptosis (3%). 5mM 
butyrate could induce significant rate increase of HepG2 apoptosis (11.98%) at 
36hour post-treatment. The apoptotic rate increased progressively from 36hour 
to72hour of treatment (Figure 3-4). The maximum value of apoptotic rate was 
20.53% at 72hour. There was no increased apoptosis of untreated cells even at 
72hour. The total cell death rate also increased progressively and reached 
53.4% at 72hour.  
 
Figure 3-4 Apoptotic assay result of HepG2 cells. 
Note: Apoptosis was measured by membrane externalization of phosphatidylserine 
using Annexin V as a sensitive probe. * indicates there is significant difference 
between treated group and control group (P<0.05) 
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3.2.2 Apoptotic assay of HCC-M 
Untreated HCC-M2 cells showed a low basal level of apoptosis (4.6%). 5mM 
butyrate could induce significant rate increase of HCC-M apoptosis (22.35%) 
at 36hour post-treatment. The apoptotic percentage rose to the maximum at 48 
hours, which is 33.4%. At 72 hours, the apoptotic percentage decreased a little 
to 32.5%. (Figure 3-5) There was no increased apoptosis of untreated cells 
even at 72hour. The total cell death percentage increased progressively, and 
reached 61.4% at 72 hours. 
 
 
Figure 3-5 Apoptotic assay result of HCC-M cells 
Note: Apoptosis was measured by membrane externalization of phosphatidylserine 
using Annexin V as a sensitive probe. * indicates there is significant difference 
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3.2.3 Comparison of apoptosis between HepG2 and HCC-M cells under 
5mM butyrate treatment 
5mM butyrate was shown to induce apoptosis in both cell lines in a 
time-dependent manner. The increase of apoptotic rate in HCC-M was more 
dramatically than the one in HepG2. There was no significant difference in the 
apoptotic rate between the two cell lines until 24hour. The significant 
difference appeared from the 36hour (P<0.05). The difference of apoptotic rate 
between the two cell lines reached a maximum of 19.2% at 48hour. At72 hour, 
the difference decreased to 11.95%, but still significant. (Figure 3-6)  
 
Figure 3-6 Comparison of apoptosis induced by 5mM butyrate between HepG2 and 
HCC-M 
Note: Apoptosis was measured by membrane externalization of phosphatidylserine 
using Annexin V as a sensitive probe. The apoptotic rate of HCC-M increased more 
dramatically than the one of HepG2. # indicates there is significant difference 
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3.3 2-D DIGE and MS results 
3.3.1 2-D DIGE of HepG2 
Internal standard, control and treated samples were labeled with Cy2, Cy3 and 
Cy5, which showed spots of yellow, green and red color, respectively, in the 
image scanned by Typhoon Variable Mode Imager. DeCyder Differential 
Analysis Software identified an average of 1937 spots from HepG2. 1002 
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pH 3                                                                     10 
Figure 3-7a HepG2 2-D DIGE image 
Note: 75μg of protein from HepG2 cells was focused on an 18cm, pH 3-10 nonlinear IPG strip 
before being separated on a 12.5% polyacrylamide gel. 25μg protein was for the internal standard, 
control and butyrate-treated (5mM) samples, respectively. The yellow color spots represented equal 
expression between control and treated samples. Green color spots represented down-regulation, 
while, red color, up-regulation with respect to the control cells.  
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pH 3                                                                         10 
Figure 3-7b HepG2 2-D silver stain image 
Note: 75μg of protein from HepG2 was focused on an 18cm, pH 3-10 nonlinear IPG strip before 
being separated on a 12.5% polyacrylamide gel. 25μg protein was for the internal standard, control 
and butyrate-treated (5mM) samples, respectively. Silver stain was done just after DIGE image 
scanning. Developing time was 2 min. 
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3.3.2 2-D DIGE of HCC-M 
Internal standard, control and treated samples were labeled with Cy2, Cy3 and 
Cy5, which showed spots of yellow, green and red color, respectively, in the 
image scanned by Typhoon Variable Mode Imager. DeCyder Differential 
Analysis Software identified an average of 1894 spots from HCC-M. 992 spots 
were matched across all 6 gels. 26 spots were found to be differentially 
expressed.
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pH 3                                                                         10 
Figrure 3-8a HCC-M 2-D DIGE image 
Note: 75μg of protein from HCC-M cells was focused on an 18cm, pH 3-10 nonlinear IPG strip 
before being separated on a 12.5% polyacrylamide gel. 25μg protein was for the internal standard, 
control and butyrate-treated (5mM) samples, respectively. The yellow color spots represented equal 
expression between control and treated samples. Green color spots represented down-regulation, 
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   pH 3                                                                        10 
Figure 3-8b HCC-M 2-D silver stain image 
Note: 75μg of protein from HCC-M was focused on an 18cm, pH 3-10 nonlinear IPG strip before 
being separated on a 12.5% polyacrylamide gel. 25μg protein was for the internal standard, control 
and butyrate-treated (5mM) samples, respectively. Silver stain was done just after DIGE image 
scanning. Developing time was 2 min 
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3.3.3 Differentially expressed proteins found commonly in both cell lines 
Following 2D DIGE and post-image analysis, 24 and 26 protein spots were 
found to be differentially expressed following treatment with 5mM butyrate in 
HCC-M and HepG2 cells respectively. From this list, 19 spots in HCC-M and18 
spots in HepG2 were identified by MALDI-TOF TOF mass spectrometry. Of 
them, 5 up-regulated and 8 down-regulated proteins were found to be common 
in both cell lines. (See Figure 3-9 and table 3-1 for the detailed information)
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pH 3                                                                      10 
Figure 3-9a Differentially regulated protein spots in HepG2, which are common to both HepG2 and 
HCC-M cells 
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pH 3                                                                        10 
Figure 3-9 b Differentially regulated protein spots in HCC-M, which are common to both HepG2 
and HCC-M cells 
























                                                      
     
Table 3-1a List of differentially expressed proteins identified by MALDI-TOF TOF Mass Spectrometry common in both cell lines 
Spot No. 
(HepG2/HCC-M)
Protein Name Accession 
No. 
Av. diff. Ratio 
(HepG2/HCC-M) 







1034/1031 Heterogeneous nuclear 
ribonucleoprotein H3  
P31942 1.68/1.87 1.80E-05/2.10E-09 36.93/6.37 42/7.6  
1102/1097 60S acidic ribosomal protein P0 P05388 1.84/1.66 4.90E-05/8.60E-06 34.27/5.72 40/6.7  
1054/1066 Annexin A1  P04083 1.77/1.65 1.90E-06/6.70E-09 38.58/6.64 42/7.5 up 
1732/1757 Deoxyuridine 5'-triphosphate 
nucleotidohydrolase, mitochondrial 
precursor 
P33316 1.64/1.52 6.60E-05/2.20E-03 26.71/9.65 23/7.5  
748/716 Keratin, type II cytoskeletal 8 P05787 1.60/1.58 0.0011/2.30E-05 51.28/5.50 55/6.01  
1961/1994 60S acidic ribosomal protein P2 P05387 -1.73/-1.50 0.0012/0.00085 11.66/4.42 17/4.4  




-1.77/-1.72 2.10E-07/6.60E-07 19.00/5.76 20/5.9  
990/990 SET protein  Q01105 -1.69/-1.73 1.60E-05/8.10E-09 33.49/4.23 48/3.93  
1771/1791 Mitochondrial import receptor subunit 
TOM22 homolog 
Q9NS69 -1.72/-1.86 0.0011/3.90E-06 15.52/4.27 21/4.4 down 
1680/1687 Telomerase-binding protein p23  Q15185 -1.84/-1.96 0.00013/6.50E-09 18.97/4.35 23/4.1  
1345/1357 Acidic leucine-rich nuclear 
phosphoprotein 32 family member B  
Q92688 -1.84/-2.43 0.0054/7.60E-07 28.79/3.94 30/3.5  
1698/1711 Nucleoside diphosphate kinase A  P15531 -2.28/-2.49 2.10E-05/8.40E-08 17.15/5.83 22/6.1  
2088/2120 Histone H4 P62805 -1.69/-2.01 0.0011/7.70E-05 11.24/11.36 10.5/4.4  
Note: Spot No., student t-test p value and average differential ratio (Av. diff. ratio) were obtained from the DeCyder software analysis. 
Accession No. was from Swiss-Prot database 
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Table 3-1b List of the matched peptides in the differentially expressed proteins common in both cell lines 
Protein Name Residues of matched peptides (HepG2) 
(Sequence coverage) 
Residues of matched peptides (HCC-M) 
(Sequence coverage) 






60S acidic ribosomal protein P0 39-44,58-63,67-92,100-162,248-264(37%) 17-44,51-62,67-92,113-162,215-220,248-264(43%) 















60S acidic ribosomal protein P2 3-21,25-41,50-94(70%) 3-21,25-94(77%) 
Translocon-associated protein, delta subunit 
precursor  
74-79,96-117,121-139(27%) 1-20,61-79,86-116,121-139(51%) 
SET protein  5-13,15-35,40-90,123-150,155-167,182-192(45%) 40-68,76-90,123-172,175-192(38%) 
Mitochondrial import receptor subunit 
TOM22 homolog 
2-22,48-58,61-82,106-117(46%) 2-22,48-82,106-142(65%) 
Telomerase-binding protein p23  36-65,72-88,96-107(36%) 13-25,36-65,72-88,96-107(45%) 
Acidic leucine-rich nuclear phosphoprotein 
32 family member B  
6-12,15-28,68-99,102-110,117-132,138-150(36%) 6-12,15-28,68-110,117-132,138-150(37%) 
Nucleoside diphosphate kinase A  2-27,35-66,86-128(66%) 7-26,35-49,57-66,86-114(48%) 
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Table 3-1c List of function of differentially expressed proteins common in both cell lines 
Protein Name Subcellular location Butyrate effect (HepG2/HCC-M) Protein function 
Heterogeneous nuclear 
ribonucleoprotein H3  
Nuclear  
    
Involved in the splicing process and 
participates in early heat shock-induced 
splicing arrest.  
60S acidic ribosomal 
protein P0 
Nuclear  
    
P0 forms a pentameric complex by 
interaction with dimers of P1 and P2. 
Annexin A1  Cytoplasmic  
    
Calcium/phospholipid-binding protein 
which promotes membrane fusion and is 
involved in exocytosis. This protein 







    
This enzyme is involved in nucleotide 
metabolism: it produces dUMP decreases 
the intracellular concentration of dUTP  
Keratin, type II 
cytoskeletal 8 
Cytoplasmic  
    
Heterotetramer of two type I and two type II 
keratins. Keratin 8 associates with keratin 
18. Interacts with HCV core protein. 
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Table 3-1c List of function of differentially expressed proteins common in both cell lines (continue) 
Protein Name Subcellular location Butyrate effect (HepG2/HCC-M) Protein function 
60S acidic ribosomal 
protein P2 
Nuclear  
    
Plays an important role in the elongation 
step of protein synthesis. P1 and P2 exist 
as dimers at the large ribosomal subunit 
Translocon-associated 
protein, delta subunit 
precursor  
Endoplasmic reticulum. 
    
TRAP proteins are part of a complex whose 
function is to bind calcium to the ER 
membrane and thereby regulate the 
retention of ER resident proteins. 
SET protein  Cytoplasmic and 
nuclear 
    
Multitasking protein, involved in 
apoptosis, transcription, nucleosome 
assembly and histone binding. 
Mitochondrial import 




    
Central receptor component of the 
translocase, which is responsible for the 
recognition and translocation of 
cytosolically synthesized mitochondrial 
preproteins 
Telomerase-binding 
protein p23  
Nuclear  
    
Molecular chaperone which can disrupts 
receptor-mediated transcriptional 
activation, by promoting disassembly of 
transcriptional regulatory complexes 
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Table 3-1c List of function of differentially expressed proteins common in both cell lines (continue) 
Protein Name Subcellular location Butyrate effect (HepG2/HCC-M) Protein function 
Acidic leucine-rich nuclear 
phosphoprotein 32 family 
member B  
Nuclear and 
cytoplasmic 
    
diffusely distributed in the cytosol. 
Inhibitor protein of protein phosphatase 
2A. Belongs to the ANP32 family. 
Nucleoside diphosphate 
kinase A  
Nuclear and 
cytoplasmic 
    
Major role in the synthesis of 
nucleoside triphosphates other than 
ATP. This protein is found in reduced 
amount in tumor cells of high 
metastasic potential. 
Histone H4 Nuclear  
    
Along with histone H3, plays a central 
role in nucleosome formation 
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3.3.4 Differentially expressed proteins found only in HepG2 
There were 5 differentially expressed proteins found only in HepG2 following treatment of 
5mM butyrate, 3 of them were up-regulated proteins, while the other 2 were down-regulated.  
pH 3                                                                      10 
 















                                                                                        





Table 3-2a List of differentially expressed proteins found in HepG2 identified by MALDI-TOF TOF Mass Spectrometry  
spot 
No. 
Protein Name Accession 
No. 
Residues of matched peptides 
(Sequence coverage) 
Av. diff.  
Ratio 












1.78 1.90E-06 39.59/6.7 43/7.5  




1.63 0.0023 45.84/9.76 19/7.2 up 






1.55 0.00094 123.67/5.51 118/7.02  




-1.5 1.40E-05 38.9/4.86 47/4.6 down 
1813 Destrin  
 
P60981 1-18,69-77,81-91,132-144,151-164(39%) -1.71 0.0005 18.37/8.12 19/7.7  
Spot No., student t-test p value and average differential ratio (Av. diff. ratio) were obtained from the DeCyder software. Accession No. was from Swiss-Prot 
database 
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Table 3-2b List of function of differentially expressed proteins found in HepG2 
Protein Name Subcellular location Butyrate effect Protein function 




May be involved in protection of liver against 
the toxic and carcinogenic effects of AFB1, a 
potent hepatocarcinogen 





May act as a transcriptional activator/repressor. 
Plays a role in the granulocyte/monocyte 
cell-specific response to interferon. 
Vinculin  Cytoplasmic face of 
adhesion plaques 
 
Involved in cell adhesion. May be involved in 
the attachment of the actin-based 
microfilaments to the plasma membrane. 
Reticulocalbin 1 precursor Endoplasmic 
reticulum  
 
May regulate calcium-dependent activities in 
the endoplasmic reticulum lumen or post-ER 
compartment. 
Destrin  Cytoplasmic  
 
Actin-depolymerizing protein. Severs actin 
filaments (F-actin) and binds to actin monomers 
(G-actin). Acts in a pH-independent manner. 
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3.3.5 Differentially expressed proteins found only in HCC-M 
There were 6 differentially expressed proteins found only in HCC-M following treatment of 
5mM butyrate, 4 of them were up-regulated, while the other 2 were down-regulated. 
pH 3                                                                     10 

















                                                                                    





Table 3-3a List of differentially expressed proteins found in HCC-M identified by MALDI-TOF TOF Mass Spectrometry  
spot 
No. 
Protein Name Accession 
No. 
Residues of matched peptides 
(Sequence coverage) 
Av. diff.  
Ratio 











2.03 2.80E-04 17.88/7.82 18.5/7.1  
1020 RGS19-interacting protein 1  O14908 10-24,58-72,81-111,191-240,249-279, 
296-307(46%) 
1.72 3.30E-07 36.04/5.90 45/7.05 up 
1498 Growth factor receptor-bound 
protein 2 
P62993  27-38,51-64,68-109,118-136,143-149, 
179-215(60%) 
1.71 5.10E-09 25.21/5.89 28/6.5  




1.55 4.10E-06 33.43/6.06 45/7.05  
1990 Ras-related protein Rab-8B Q92930 2-46,59-94,105-116,154-175,177-197, 
199-207(70%) 
-1.57 2.10E-03 23.58/9.15 19/5.2 down 
1913 Calmodulin (CaM) P62158 1-37,76-148(74%) -2.23 5.10E-07 16.71/4.09 20/3.5  
Note: Spot No., student t-test p value and average differential ratio (Av. diff. ratio) were obtained from the DeCyder software.  
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Table 3-3b List of function of differentially expressed proteins found in HCC-M 





Accelerate the folding of proteins. It catalyzes the 
cis-trans isomerization of proline imidic peptide 
bonds in oligopeptides. 
RGS19-interacting protein 1  Cytoplasmic and 
membrane-associated
 
May be involved in G protein-linked signaling 
and inhibit voltage-independent calcium channel. 




Associates with activated Tyr-phosphorylated 
EGF receptors and PDGF receptors via its SH2 
domain. GRB2 also associates to other cellular 
Tyr-phosphorylated proteins such as IRS1, SHC 
and LNK. 




liver-specific. Reduces the gamma-methene 
bridge of the open tetrapyrrole, biliverdin IX 
alpha, to bilirubin with the concomitant oxidation 
of a NADH or NADPH cofactor. 
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Table 3-3b List of function of differentially expressed proteins found in HCC-M (continue) 
Protein Name Subcellular location Butyrate effect Protein function 
Ras-related protein Rab-8B Cytoplasmic  
 
Belongs to the small GTPase 
superfamily. Rab family. May be 
involved in vesicular trafficking 
and neurotransmitter release 
Calmodulin (CaM) Cytoplasmic  
 
Mediates the control of a large 
number of enzymes by Ca2+. Among 
the enzymes to be stimulated by the 
calmodulin-Ca(2+) complex are a 
number of protein kinases and 
phosphatases. 
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3.3.5.1 Up-regulation of RGS19-interacting protein 1 
RGS19-interacting protein 1 was found to be up-regulated in 5mM butyrate 
treated HCC-M cells. The Decyder analysis and MALDI-TOF mass spectrum 
results are shown in Figure 3-12b and 3-12c, respectively. Figure 3-12d showed 
the matched peptides in the sequence. 
 
                         DIGE            Control          Treated 
Figure 3-12a 2-D DIGE and silver stain image of RGS19-interacting protein 1.  





















Figure 3-12b Decyder analysis result of RGS19-interacting protein 1 
 
                                                                   Chapter III                      
                                                     - 93 - 
  
 




Figure 3-12d Matched residues of peptides of RGS19-interacting protein 1 
Note: Sequence coverage: 46%. Matched residues of peptides were shown in Bold 
Red 
1            10            20            30            40            50 
 MPLGLGRRKK APPLVENEEA EPGRGGLGVG EPGPLGGGGS GGPQMGLPPP 
51          60            70           80            90            100 
 PPALRPRLVF HTQLAHGSPT GRIEGFTNVK ELYGKIAEAF RLPTAEVMFC 
101          110           120          130           140          150 
TLNTHKVDMD KLLGGQIGLE DFIFAHVKGQ RKEVEVFKSE DALGLTITDN 
151        160          170          180          190           200 
GAGYAFIKRI KEGSVIDHIH LISVGDMIEA INGQSLLGCR HYEVARLLKE 
201         210            220           230           240           250 
LPRGRTFTLK LTEPRKAFDM ISQRSAGGRP GSGPQLGTGR GTLRLRSRGP  
251         260           270           280           290           300 
ATVEDLPSAF EEKAIEKVDD LLESYMGIRD TELAATMVEL GKDKRNPDEL  
301          310          320           330  333 
AEALDERLGD FAFPDEFVFD VWGAIGDAKV GRY  
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3.3.5.2 Down-regulation of calmodulin in HCC-M cells 
Calmodulin was found to be down-regulated in 5mM butyrate treated HCC-M 
cells. The Decyder analysis and MALDI-TOF mass spectrum results are shown 
in Figure 3-13b, and 3-13c, respectively. Figure 3-13d showed the matched 
peptides in the sequence. 
 
                         DIGE           Control          Treated 
Figure 3-13a 2-D DIGE and silver stain image of calmodulin.  
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Figure 3-13c MALDI-TOF mass spectrum of calmoduin 
 
 
Figure 3-13d Matched residues of peptides of calmodulin 
Note: Sequence coverage: 74%. Matched residues of peptides were shown in Bold 
Red
1           10           20            30             40            50 
ADQLTEEQIA EFKEAFSLFD KDGDGTITTK ELGTVMRSLG QNPTEAELQD  
51          60          70              80           90            100 
MINEVDADGN GTIDFPEFLT MMARKMKDTD SEEEIREAFR VFDKDGNGYI 
101         110            120          130            140          148 
SAAELRHVMT NLGEKLTDEE VDEMIREADI DGDGQVNYEE FVQMMTAK  
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3.4 2-DE western blot of RGS19 interacting protein 1 
2-DE western blot was carried out to confirm the protein identification of 
RGS19-interacting protein 1. There were a total of six spots appearing after 
immunoblotting detection. Five of them were at the same molecular weight 
position, while one was at a slightly higher position. The arrow points to a spot 
which denotes RGS-19 interacting protein 1 according to the original 
experimental position of both PI (7.05) and MW (45kDa). Other spots could be 
due to the non-specificity using polyclonal primary antibody or the 
post-transcription modification of the protein, such as phosphorylation.  
pH 3                                        10 
 
Figure 3-14 2-DE western blot result of RGS-19 interacting protein 1. 
Note: 30μg of sample from treated HCC-M cells was focused on a 7cm pH3-10 
non-linear IPG strip before being separated on a 12.5% polyacrylamide gel. The 
proteins then were transferred to PVDF membrane. Polyclonal chicken 
Affi-anti-RGS19IP1 IgY and advanced ECL detection kit were used to probe the 
protein. The spot which the arrow denotes should be RGS-19 interacting protein 
1according to its original position in 2-DE image.  
                                                                          Chapter IV 
 














                                                                          Chapter IV 
 
                                                                             - 98 - 
4.1 Comparison of difference between HepG2 and HCC-M 
Although both HCC-M and HepG2 belong to the epithelial type of 
hepatocellular carcinoma, their origins are different. HCC-M was established 
from an adult (Watanabe, et al., 1983), while HepG2 was from a 15 year-old 
boy (Aden, et al., 1979). Onset of hepatocellular carcinoma is common after 40 
years of age in both genders (Lee, et al., 1993; Parkin, et al., 2002). However, 
the formation of a tumor from a young person often meant a higher level of 
carcinoma malignancy and metastasis. HepG2 can secrete alpha-fetoprotein 
(AFP), while HCC-M has no such characteristic. AFP is a well-known 
biomarker for hepatocellular carcinoma which has a positive correlation with 
metastasis but a negative relationship for cell differentiation of HCC (Jiang, et 
al., 2000; Molmenti, et al., 2001). In our cell culture experiments, we did 
observe that HepG2 proliferate at higher rates and with smaller and more 
spherical cell body compared to HCC-M. Therefore, there could be some 
difference in the degree of differentiation and ability of metastasis between 
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4.2 Butyrate can induce apoptosis in both HepG2 and HCC-M 
Previous publications reported that low concentration of butyrate (1mM) could 
inhibit the cell growth of HepG2 (Bode, et al., 1994), and high concentration 
(35mM) could induce apoptosis (Wang, et al., 1998, 1999). For HCC-M, Saito 
H. et al. reported that low concentration of butyrate could only induce cell 
differentiation, but not apoptosis even when the concentration was increased to 
5mM. (Saito, et a.l, 1998) In our study, 5mM is the key treatment point at 
which HepG2 and HCC-M showed different response from each other. After 
24hour, cell viablity of HCC-M was inhibited completely, while HepG2 could 
still proliferate with a lower rate than the control. With the treatment of 5mM 
butyrate, about one-third of HCC-M cells exhibited apoptosis within 48 hours. 
This is the highest apoptotic percentage, after which cell entered a necrotic 
condition. HepG2 also showed an apoptotic effect, but not in a drastic way. Our 
experimental results about the effect of hutyrate on HCC-M are different from 
the previous publications as described above. This maybe due to the different 
culture condition, experimental methods, and/or other unknown reasons. 
Further study is needed to elucidate the argument. 
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4.3 Butyrate induces different apoptotic response in HepG2 and HCC-M 
It has been studied for several years that butyrate could act as both cell 
differentiation and apoptosis inducer on many cancer cell lines, including 
HepG2 and HCC-M. However, no publication has focused on the comparison 
of their effects. Actually anticancer drugs at specific concentration often 
produce different outcome even though they act in the same type of cancer cell 
but with different level of differentiation. In our study, MTT assay showed that 
5mM butyrate could completely inhibit HCC-M cell growth, while HepG2 
cells’ growth was only partially inhibited. It was observed from apoptosis assay 
that after 48hour of treatment with 5mM butyrate, the rate of apoptosis in 
HCC-M peaked. However, the apoptotic rate of HepG2 kept rising but always 
less than that of HCC-M until the last experimental time point of 72hour. The 
total cell death rate of both cell lines kept rising during the whole time course, 
but HCC-M consistently exhibited a higher death rate than HepG2 from 
36hours onwards. Both experiments support our hypothesis that HCC-M 
seemed more sensitive to the butyrate treatment at the concentration of 5mM 
than HepG2, either in cytotoxicity or apoptosis. Referring to the different 
biological characteristics between HepG2 and HCC-M, the result could provide 
us some clues for the discovery of therapeutic targets in hepatocellular 
carcinoma, if we could clarify the molecular basis of the different response 
                                                                          Chapter IV 
 
                                                                             - 101 - 
induced by butyrate. 
4.4 Differentially expressed proteins that are related to butyrate induced 
apoptosis 
Proteins are the direct executors of biochemical functions of the living cell. 
Under stimulation, the expression level of relevent proteins in cells may change. 
We applied 2D DIGE-MS to identify the differentially regulated proteins and 
possible signal pathways related to the differential sensitivities of the two cell 
lines to 5mM butyrate treatment. There were 24 proteins identitified in both cell 
lines, which belonged to different subcellular location and functional 
categories.( as shown in Figure 4-1)  
The differentially regulated proteins were compared between the two cell lines. 
5 up-regualted and 8 down-regulated proteins were found in both cell lines, 
which represented more than 50% of the total differentially expressed proteins 
in each cell line. The up-regulated proteins included heterogeneous nuclear 
ribonucleoprotein H3 (hnRNP H3), 60S acidic ribosomal protein P0 (L10E), 
annexin A1, deoxyuridine 5'-triphosphate nucleotidehydrol- ase (mitochondrial 
precursor) (dUTPase) and keratin (type II cytoskeletal 8) (Cytokeratin 8). The 
down-regulated proteins were 60S acidic ribosomal protein P2, SET protein, 
Translocon-associated protein (delta subunit precursor) (TRAP-delta), 
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mitochondrial import receptor subunit TOM22 homolog (hTom22), 
telomerase-binding protein p23 (Hsp90 co-chaperone), acidic leucine-rich 
nuclear phosphoprotein 32 family member B (PHAPI2 protein), nucleoside 
diphosphate kinase A (NDK A) and histone H4. (Table 3-1a) 
Most of these were cancer related proteins, such as heterogeneous nuclear 
ribonucleoprotein H3 (Mahe, et al., 2000), annexin A1 (Debret, et al., 2003), 
deoxyuridine-5'- triphosphate nucleotidohydrolase (Ladner, 2001), keratin (type 
II cytoskeletal 8) (Gires, et al., 2005), SET protein (Fan, et al., 2003), 
telomerase-binding protein p23 (Young, et al., 2000), acidic leucine-rich 
nuclear phosphoprotein 32 family member B (Zhu, et al., 1997), nucleoside 
diphosphate kinase A (Almgren, et al., 2004) and histone H4 (Fraga, et al., 
2005). SET protein and telomerase-binding protein p23 were protein chaperons 
which were involved in cell apoptosis-induced stimuli. Some were related to the 
nuclear reformation, such as 60S acidic ribosomal protein P0 (Beausoleil, et al., 
2004). Mitochondrial import receptor subunit TOM22 homolog (Saeki, et al., 
2000), 60S acidic ribosomal protein P2 (Rich, et al., 1987) and 
translocon-associated protein (Holthuis, et al., 1995) were related to protein 
synthesis and transportation. Annexin A1 and Translocon-associated protein 
were also involed in calcium-mediated cell event (Figure 4-1). All these 
proteins may be commonly responsible for the growth inhibition and apoptosis 
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induced by butyrate in both cell lines. Other than these, there were some 
dfferentially expressed proteins found exclusively only in either HepG2 or 




Figure 4-1 Schematic representation of the proteins differentially expressed in treated 









HnRNP H3 , annexin A1, dUTPase, 
cytokeratin 8, SET protein, Hsp90 
co-chaperone, PHAPI2 protein, NDK A, 
histone H4 
Cancer-related protein 
60S acidic ribosomal protein P0 
Nuclear or cytoskeleton reformation 
AFB1-AR 1,  
myeloid cell nuclear 
differentiation 
antigen,  





Protein synthesis and transportation 
60S acidic ribosomal protein P2, 





PPIase , TIP-2 , 
BVR A  
Ras-related 
protein Rab-8B 
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4.4.1 Differentially expressed proteins present only in HepG2 
Up-regulation of aflatoxin B1 aldehyde reductase member 2, myeloid cell 
nuclear differentiation antigen and vinculin, and down-regulation of 
reticulocalbin 1 precursor and destrin were found only in HepG2 cells. 
Aflatoxin B1 aldehyde reductase member 2 (Hayes, et al., 1993; Praml, et al., 
2003) and myeloid cell nuclear differentiation antigen (Burrus, et al., 1992) 
were cancer-related proteins, which were also found to be up-regulated in other 
cancer cells treated by anti-cancer agent. Reticulocalbin 1 was also a type of 
cancer-related and calcium-binding protein, which was reported to be 
down-regulated in treated nasopharyngeal carcinoma cell line, CNE2 with 
12-O-tetradecanoylphorbol-13-acetate (TPA). In this study, TPA induced 
anti-proliferation and apoptosis of CNE2 (Jiang, et al., 2005). In our experiment, 
the down-regulation of reticulocalbin was also found in butyrate treated HepG2, 
which supported its involvement in the apoptosis of cancer cell lines. Vinculin 
(Chen, et al., 2005) and destrin (Yahara, et al., 1996) were related to the 
adhesion and cytoskeleton reformation in the cellular dynamics under the cell 
stimuli. Down-regulation of vinculin was found in 5α-pregnane-3, 20-dione 
treated MCF-7 breast cancer cells, while 5α-pregnane-3, 20-dione has been 
shown to stimulate proliferation and to decrease adhesion of MCF-7 (Wiebe, et 
al., 2001). Up-regulation of destrin was found in malignant lung epithelial cells, 
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A549, compared to the normal one (Chang, et al., 2001). Up-regualtion of 
vinculin and down-regulation of destrin in butyrate treated HepG2 cells 
suggested that the associated cell adhesion alteration and cytoskeleton 
reformation could be induced by butyrate in HCC. 
4.4.2 Differentially expressed proteins present only in HCC-M 
Up-regulation of peptidyl-prolyl cis-trans isomerase A (PPIase), 
RGS19-interacting protein 1 (TIP-2), growth factor receptor-bound protein 2 
(GRB2 adapter protein) and biliverdin reductase A precursor (BVR A), and 
down-regulation of ras-related protein Rab-8B and calmodulin were found only 
in HCC-M. Peptidyl-prolyl cis-trans isomerase A was protein chaperon, and 
could interact specifically with the phosphorylated form of nuclear factor of 
activated T cells (NFAT) and regulate calcium-dependent activation of NFAT in 
vivo (Liu, et al., 2001). Ras-related protein Rab-8B could interact with TRIP8b 
and are involved in regulated secretory pathway (Chen, et al., 2001). Growth 
factor receptor-bound protein 2 (Wada, et al., 1998) and biliverdin reductase A 
(Baranano, et al., 2002) were involved in cell growth or cell protection from 
stress stimuli. All the proteins were related to the cell differentiation or 
apoptosis event. Among them, the up-regulation of Growth factor 
receptor-bound protein 2 and biliverdin reductase A seemed conflicted with the 
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apoptotic effect of butyrate on HCC-M cells. We hypothesized that they were 
the early protective response of HCC-M cells to the apoptotic stimuli, because 
the treatment time was only 24 hours. Further studies are needed to clarify the 
expression change of the two proteins in time course after 24hour treatment.   
RGS19-interacting protein 1 and calmodulin were involved in calcium signal 
pathway. The dysregulation of RGS19-interacting protein 1 and calmodulin 
simultaneously in HCC-M under the butyrate treatment was highlighted as a 
potential reason for the higher sensitivity of HCC-M to the butyrate. 
4.4.2.1 Function of up-regulated RGS19-interacting protein 1 in HCC-M 
apoptosis 
RGS19 interacting protein 1 is the regulator of G protein signaling. It can 
interact with Gα subunit of G protein and selectively activate Go (a member of 
G protein family)-mediated pathways that inhibit voltage-independent Ca2+ 
channel. (Tosetti, et al., 2002)  
In all eukaryotic cells, Ca2+ is required in both the extracellular environment 
and intracellular stores for cell growth and division. Depletion of intracellular   
stores resulted in cell growth arrest. For example, some pharmacological agents, 
such as thapsigargin or 2, 5-di-tert-butylhydroquinone, resulted in a cessation of 
cell division (Short, et al., 1993). These agents block the Ca2+ pumping ATPase 
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present in the endoplasmic reticulum and result in a depletion of Ca2+ stores in 
the endoplasmic reticulum. The consequences of intracellular Ca2+ pool 
depletion included inhibition of DNA synthesis, protein synthesis, and nuclear 
transport. (Short, et al., 1993; Greber, et al., 1995; Hussain, et al., 1995) 
The role of Ca2+ channel inhibition on cell apoptosis is complicated depending 
on different types of organisms and physiological conditions. Sometimes, 
inhibition of Ca2+ channel may lead to protective effect from apoptosis, because 
the apoptosis-inducible Ca2+ overload is repressed. (Pigozzi, et al., 2004; Zhou, 
et al., 2004) Sometimes Ca2+ channel inhibition may induce apoptosis, 
especially in cancer cell, possibly because the cytosolic Ca2+ homeostasis which 
cell proliferation relies on is perturbed. (Oh, et al., 2003; Namgung, et al., 2003) 
A recent publication (Winters, et al., 2005) reported that carboxyamido-triazole 
(CAI), a voltage-independent calcium channel inhibitor, has been shown to 
induce growth inhibition and apoptosis in cancer cells. Treatment with CAI 
suppressed the extracellular signal-regulated kinase pathway within the first 
hour but ultimately results in high, sustained activation of ERK over a 9-day 
period. Suppression of cyclin D1 and phospho-AKT, and cleavage of caspase-3 
and PARP were concomitant with persistent ERK activation.  
In brief, our study suggested that butyrate induced up-regulation of 
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RGS19-interacting protein in HCC-M, which could in turn inhibit the Ca2+ 
channel by activating the Go-mediated pathways. Ca2+ channel inhibition could 
induce deficiency of intracellular Ca2+, which may lead to persistent activation 
of ERK, as well as consequent suppression of cyclin D1 and phospho-AKT, 
cleavage of caspase-3 and PARP, and finally apoptosis. Further work is needed 
to elucidate if butyrate really elicits the decreasing of intracellular Ca2+ 
concentration in HCC-M as well as the up and downstream molecules in the 
Ca2+ related signal pathway. (Figure 4-2) 
4.4.2.2 Function of down-regulated calmodulin in HCC-M apoptosis 
In mammalian cells, CaM is a 148-amino acid, highly conserved Ca2+ binding 
protein that contains four EF-hand Ca2+ binding motifs (Chin, et al., 2000). 
Based on nuclear magnetic resonance and crystal structures of CaM in the apo 
and Ca2+ -bound state, we know that Ca2+ -bound CaM has a dumbbell shape 
with two EF-hand motifs on either end connected by a central helix (Chin, et al., 
2000; Tjandra, et al., 1999). Ca2+ binding exposes hydrophobic patches, 
promoting interaction with target enzymes. A number of crystal structures of 
Ca2+ /CaM bound to target peptides demonstrate that CaM wraps around the 
target peptide, engulfing it (Tjandra, et al., 1999; Meador, et al., 1992; 1993; 
Roth, et al., 1991; 1992).  
                                                                          Chapter IV 
 
                                                                             - 109 - 
For targets of Ca2+ /CaM, this binding has enormous consequences. CaM 
regulates numerous intracellular enzymes that include phosphodiesterases, 
adenylyl cyclases, ion channels, protein kinases, and protein phosphatases 
(Chin, et al., 2000). Ca2+/CaMdependent pathways are involved in the 
regulation of a wide variety of cellular processes including secretion, cell 
motility, ion homeostasis, gene transcription, neurotransmission, and 
metabolism. Hormone and neurotransmitter stimulation of cells leads to a 
variety of Ca2+/CaM-mediated responses. (Gnegy, 1993) Initially, hormone 
receptors are activated, leading to an intracellular Ca2+ rise. Ca2+ regulates some 
targets directly and other targets indirectly through Ca2+ binding proteins, such 
as CaM. Persistent stimulation can cause changes in the subcellular distribution 
of CaM, which leads to changes in Ca2+/CaM responsiveness in a given area of 
the cell. Long term stimulation can also lead to changes in the total amount of 
CaM making a cell more or less sensitive to Ca2+ signals (Gnegy, 1993). 
As the major intracellular Ca2+-binding protein, CaM plays a critical role in the 
regulation of cell proliferation. Cell growth is coordinately regulated by calcium 
and CaM. (Rasmussen, et al., 1992; Bachs, et al., 1992)  It has been reported 
that diseases characterized by pathological, unregulated cell growth, such as 
cancer, are associated with elevated levels of Ca2+-bound CaM. (Wei, et al., 
1982; Hait, et al., 1986)  CaM antagonists have been shown to inhibit tumor 
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cell invasion in vitro (Dewhurst, et al., 1997) and metastasis in vivo (Ito, et al., 
1991). The CaM antagonist, TFP, induces apoptosis in cancer cell lines. (Pan, et 
al., 1999) Growth inhibition and induction of apoptosis by TMX, an 
anti-estrogen that is also a potent CaM inhibitor, have been observed in human 
cancers and cancer cell lines, and maybe Fas-mediated. (Pan, et al., 1999; 
Sampson, et al., 1997; Kim, et al., 1999) The molecular mechanisms of CaM 
antagonist-mediated apoptosis remain poorly understood. Recent publication 
reported that during CaM antagonist-mediated apoptosis in IFN- -pretreated 
Fas-low cells, cleavage of caspases-8, -9, and -3 and Bid, release of cytochrome 
c from the mitochondria and an increase in the free cytosolic calcium 
concentration were observed. (Ahn, et al., 2003) (Shown in Figure 4-2) 
In our experiment, 5mM butyrate may induce both Ca2+ channel inhibition and 
CaM down-regulation in HCC-M, which implied that the overlay effect may 
cause the quicker cell apoptosis than the one in HepG2. 
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Figure 4-2 Scheme of potential signal pathway of apoptosis induced by butyrate with 
RGS19 interacting protein 1 and calmodulin involved in HCC-M 
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4.5 Conclusion 
5mM butyrate treatment could induce growth inhibition and apoptosis in both 
HCC-M and HepG2 cells, but HCC-M cells were more sensitive to the 
treatment than HepG2, in either the inducible cytotoxicity or apoptosis. 18 
differentially regulated proteins from HepG2 cells and 19 from HCC-M cells 
were identified by 2D-DIGE mass spectrometry. Among them, up-regulation of 
RGS19-interacting protein 1 and down-regulation of calmodulin in HCC-M 
may explain the higher sensitivity of HCC-M to the butyrate-induced-apoptosis. 
They were both related to the calcium-mediated signal pathway. Up-regulation 
of RGS19-interacting protein 1 could inhibit voltage-independent calcium 
channel and may lead to deficiency of intracellular calcium. Deficiency of 
intracellular calcium and down-regulation of calmodulin could form overlay 
effect to induce quicker apoptosis in HCC-M by the treatment of butyrate. 
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